<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1243286</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2023.1243286</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Compounds targeting ferroptosis in breast cancer: progress and their therapeutic potential </article-title>
<alt-title alt-title-type="left-running-head">Xu et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2023.1243286">10.3389/fphar.2023.1243286</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Xu</surname>
<given-names>Chuchu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Chen</surname>
<given-names>Yian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Qinghong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Song</surname>
<given-names>Jiaqing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jin</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gao</surname>
<given-names>Xiufei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1740687/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>The First Clinical Medical College of Zhejiang Chinese Medical University</institution>, <addr-line>Hangzhou</addr-line>, <addr-line>Zhejiang</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Breast Surgery</institution>, <institution>The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine</institution>, <addr-line>Hangzhou</addr-line>, <addr-line>Zhejiang</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/299382/overview">Jianqiang Xu</ext-link>, Dalian University of Technology, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/404929/overview">Jinke Wang</ext-link>, Southeast University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/307971/overview">S. Paul Gao</ext-link>, Memorial Sloan Kettering Cancer Center, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1173475/overview">Can Hu</ext-link>, University of Chinese Academy of Sciences, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Xiufei Gao, <email>gaoxiufei@zcmu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>10</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1243286</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>06</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>10</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Xu, Chen, Yu, Song, Jin and Gao.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Xu, Chen, Yu, Song, Jin and Gao</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>In recent years, there has been a significant increase in the incidence of Breast cancer (BC), making it the most common cancer among women and a major threat to women&#x2019;s health. Consequently, there is an urgent need to discover new and effective strategies for treating BC. Ferroptosis, a novel form of cell death characterized by the accumulation of iron-dependent lipid reactive oxygen species, has emerged as a distinct regulatory pathway separate from necrosis, apoptosis, and autophagy. It is widely recognized as a crucial factor in the development and progression of cancer, offering a promising avenue for BC treatment. While significant progress has been made in understanding the mechanisms of ferroptosis in BC, drug development is still in its early stages. Numerous compounds, including phytochemicals derived from dietary sources and medicinal plants, as well as synthetic drugs (both clinically approved medications and laboratory reagents), have shown the ability to induce ferroptosis in BC cells, effectively inhibiting tumor growth. This comprehensive review aims to examine in detail the compounds that target ferroptosis in BC and elucidate their potential mechanisms of action. Additionally, the challenges associated with the clinical application of ferroptosis-inducing drugs are discussed, offering valuable insights for the development of novel treatment strategies for BC.</p>
</abstract>
<kwd-group>
<kwd>breast cancer</kwd>
<kwd>ferroptosis</kwd>
<kwd>ferroptosis-inducing agents</kwd>
<kwd>drugs</kwd>
<kwd>natural compounds</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pharmacology of Anti-Cancer Drugs</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>According to the latest global cancer statistics, the incidence of Breast cancer (BC) has reached the first place among all cancer types in women, surpassing lung cancer (<xref ref-type="bibr" rid="B97">Sung et al., 2021</xref>). The current treatment options for BC include surgery, radiotherapy, chemotherapy, hormonal therapy, and targeted therapy (<xref ref-type="bibr" rid="B40">Gradishar et al., 2022</xref>). These therapies have significantly enhanced the survival rates for BC patients. Nevertheless, approximately 10%&#x2013;15% of patients with early-stage BC still face the risk of local recurrence during long-term follow-up. Tragically, some of these patients succumb to tumor progression or treatment failure (<xref ref-type="bibr" rid="B90">Sopik et al., 2016</xref>). Therefore, it is crucial to find more effective treatment strategies for BC. Recent research has highlighted the significant role of ferroptosis in various diseases, such as neurodegenerative diseases (<xref ref-type="bibr" rid="B123">Yao M-Y. et al., 2021</xref>), cancer (<xref ref-type="bibr" rid="B132">Zhang C. et al., 2022</xref>), cardiovascular diseases (<xref ref-type="bibr" rid="B109">Wu et al., 2021</xref>), and chronic kidney disease (<xref ref-type="bibr" rid="B145">Zhou Y. et al., 2022</xref>). Ferroptosis, a distinct form of cell death separate from apoptosis, autophagy, and necrosis, is characterized by excessive accumulation of lipid hydroperoxides to lethal levels in iron-dependent pathways (<xref ref-type="bibr" rid="B98">Tang and Kroemer, 2020</xref>). Mounting evidence suggests that ferroptosis inhibits tumor cell growth, making it a promising target for anticancer therapy (<xref ref-type="bibr" rid="B17">Chen et al., 2021</xref>). Significant progress has been made in recent years regarding ferroptosis research in BC, particularly in understanding its mechanisms. For instance, Xie Y et al. (<xref ref-type="bibr" rid="B110">Xie et al., 2022a</xref>), discovered that mammary adipocytes could protect BC cells from ferroptosis via oleic acid in the presence of ACSL3. Additionally, the role of non-coding RNA has been elucidated in BC, which includes circular RNA, microRNA, and lncRNA, in BC development (<xref ref-type="bibr" rid="B74">Mao et al., 2018</xref>; <xref ref-type="bibr" rid="B134">Zhang H. et al., 2021</xref>; <xref ref-type="bibr" rid="B7">Bazhabayi et al., 2021</xref>; <xref ref-type="bibr" rid="B133">Zhang et al., 2023</xref>). However, there are currently no drugs specifically designed for ferroptosis in BC. Consequently, exploring drug-induced ferroptosis in BC represents a promising and valuable avenue of research (<xref ref-type="bibr" rid="B92">Sui et al., 2022</xref>). This review aims to summarize the compounds capable of inducing ferroptosis in BC, encompassing both natural phytochemicals and chemically synthesized drugs. It is expected to provide valuable insights for future drug development in the field of ferroptosis induction for BC.</p>
</sec>
<sec id="s2">
<title>2 Mechanism of ferroptosis in BC</title>
<p>The regulation of ferroptosis is primarily governed by three essential components: reactive oxygen species (ROS), the interaction between glutathione (GSH), ROS facilitated by Glutathione Peroxidase 4 (GPX4), and the induction of lipid peroxidation catalyzed by arachidonic acid lipoxygenase (ALOX) (<xref ref-type="bibr" rid="B92">Sui et al., 2022</xref>). In the process of ferroptosis, iron triggers an excessive generation of ROS through the Fenton reaction. Therefore, ferroptosis is an iron-dependent process (<xref ref-type="bibr" rid="B84">Rizzollo et al., 2021</xref>). Given the extensive array of mechanisms associated with ferroptosis, this summary will focus on the key mechanisms relevant to compounds-induced ferroptosis in BC.</p>
<sec id="s2-1">
<title>2.1 The role of GPX4 and system xc</title>
<p>GPX4 is a selenoenzyme that plays a crucial role in inhibiting ferroptosis by converting toxic phospholipid hydroperoxides (PLOOHs) into non-toxic phospholipid alcohols (PLOHs) (<xref ref-type="bibr" rid="B121">Yang et al., 2014</xref>). The system xc-consists of two components: a light chain (xCT, transcribed from SLC7A11) and a heavy chain (4F2, transcribed from SLC3A2) (<xref ref-type="bibr" rid="B50">Huang et al., 2005</xref>). This system functions by exporting glutamate out of the cell while simultaneously importing cystine into the cell in a 1:1 ratio (<xref ref-type="bibr" rid="B87">Sato et al., 1999</xref>). Once inside the cell, cystine is rapidly converted to L-cysteine, which serves as a crucial building block for the synthesis of intracellular glutathione (GSH). GSH is the most abundant and ubiquitous antioxidant in cells. It plays a vital role in restoring the intracellular reduction-oxidation (REDOX) balance following the generation of ROS. And it is also a necessary substrate for GPX4 enzymatic activity (<xref ref-type="bibr" rid="B79">Niu et al., 2021</xref>). Erastin and RSL3 are the classical ferroptosis inducer. Erastin inhibits GPX4 activity by depleting cellular GSH, while RSL3 directly targets and inhibits GPX4 activity (<xref ref-type="bibr" rid="B121">Yang et al., 2014</xref>). Cells expressing high levels of SLC7A11 and SLC3A2 are capable of sustaining GPX4 expression through selenocysteine biosynthesis. Meanwhile these cells are more resistant to lipid peroxidation-induced cell death (<xref ref-type="bibr" rid="B62">Lee et al., 2021a</xref>). Methyltransferase METTL16 boosts GPX4 expression by means of epigenetic modification of N6-methyladenosine (m6A), thus inhibiting ferroptosis and facilitating the progression of BC (<xref ref-type="bibr" rid="B126">Ye et al., 2023</xref>). Different subtypes of triple-negative breast cancer (TNBC) exhibit distinct characteristics regarding their susceptibility to ferroptosis treatment, with the luminal androgen receptor (LAR) subtype being particularly sensitive to ferroptosis induction (<xref ref-type="bibr" rid="B116">Yang et al., 2023a</xref>).</p>
</sec>
<sec id="s2-2">
<title>2.2 Iron metabolism</title>
<p>Iron metabolism plays a critical role in ferroptosis, with free iron serving as the foundation for this process (<xref ref-type="bibr" rid="B25">Dixon et al., 2012</xref>). Ferritin is a cytosolic iron storage protein. It is composed of two subunits, ferritin heavy chain 1 (FTH1) and ferritin light chain (FTL) (<xref ref-type="bibr" rid="B18">Chen X. et al., 2020</xref>). The vast majority of intracellular Fe<sup>2&#x2b;</sup> is stored in ferritin in the form of labile iron pool (LIP). Excessive levels of free iron can trigger the peroxidation of polyunsaturated fatty acids (PUFA), leading to the generation of lipid peroxides. This process disrupts the structure of cell membranes and initiates ferroptosis through the Fenton reaction (<xref ref-type="bibr" rid="B25">Dixon et al., 2012</xref>). Transferrin (TF) is a vital iron-binding protein that transports extracellular iron into cells by binding to transferrin receptors on the cell membrane. This process involves the participation of two distinct isoforms of transferrin receptors, namely, transferrin receptor 1 (TFR1) and transferrin receptor 2 (TFR2) (<xref ref-type="bibr" rid="B39">Gomme et al., 2005</xref>). IRP1 and IRP2, members of the iron regulatory protein (IRP) family, maintain intracellular iron homeostasis by regulating the expression of genes related to iron metabolism (<xref ref-type="bibr" rid="B76">Muckenthaler et al., 2008</xref>; <xref ref-type="bibr" rid="B59">K&#xfc;h and n, 2015</xref>). Ferroportin (FPN) functions as an iron efflux pump responsible for expelling intracellular iron from the cell, and it serves as a suppressor of ferroptosis (<xref ref-type="bibr" rid="B91">Su et al., 2020</xref>). Yu H et al. (<xref ref-type="bibr" rid="B130">Yu et al., 2019</xref>), observed that transferrin receptor (TFRC) expression was significantly higher in ER-tissues compared to ER &#x2b; tissues, and knockdown of estrogen receptor (ER) increased TFRC expression in BC cells. Additionally, sulfasalazine (SAS) can induce ferroptosis in BC cells, particularly in cells with low ER expression.</p>
</sec>
<sec id="s2-3">
<title>2.3 Ferroptosis-related autophagy</title>
<p>Autophagy is an intracellular degradation process that transports cellular components to lysosomes for degradation (<xref ref-type="bibr" rid="B36">Feng et al., 2014</xref>). Recent studies have revealed that heightened autophagy and lysosomal activity could contribute to the promotion of ferroptosis by facilitating iron accumulation or lipid peroxidation (<xref ref-type="bibr" rid="B142">Zhou et al., 2020</xref>). Specifically, autophagy in ferroptosis includes ferritin autophagy, adipoautophagy, clock autophagy, and chaperone-mediated autophagy (<xref ref-type="bibr" rid="B68">Liu et al., 2020</xref>). They promote ferroptosis by degrading antiferroptosis regulators, namely, ferritin, lipid droplets, ARNTL, and GPX4 (<xref ref-type="bibr" rid="B98">Tang and Kroemer, 2020</xref>). Ferritin autophagy is a process of degrading ferritin through autophagy. The liberation of free iron results in elevated iron levels, triggering the Fenton reaction and subsequent oxidative stress, ultimately leading to ferroptosis (<xref ref-type="bibr" rid="B31">Dowdle et al., 2014</xref>; <xref ref-type="bibr" rid="B47">Hou et al., 2016</xref>). For example, E3 ubiquitin ligase promotes the degradation or transport of target proteins by linking ubiquitin molecules to specific sites of target proteins. The E3 ligases NEDD4 and NEDD4L inhibit ferroptosis by promoting the degradation of mitochondrial voltage-dependent anion channels (VDAC) and lactotransferrin, respectively. Nuclear receptor coactivator 4 (NCOA4) is a selective cargo receptor for autophagic turnover of ferritin by lysosomes. The depletion of NCOA4 or autophagy-related (ATG, such as ATG3, ATG5, ATG7, and ATG13) can impede ferritin degradation, resulting in the buildup of iron and lipid peroxidation, ultimately leading to ferroptosis (<xref ref-type="bibr" rid="B73">Mancias et al., 2014</xref>).</p>
</sec>
<sec id="s2-4">
<title>2.4 Lipid metabolism</title>
<p>Numerous recent studies have provided compelling evidence linking dysregulated fatty acid (FA) metabolism to cancer development (<xref ref-type="bibr" rid="B85">R&#xf6;hrig and Schulze, 2016</xref>). Notably, the accumulation of PUFA oxides stands as a hallmark of ferroptosis, which represents a distinct form of cell death (<xref ref-type="bibr" rid="B127">Ye et al., 2020</xref>). Intracellular ROS readily oxidize PUFA, leading to the formation of lipid peroxides that strongly promote the initiation of ferroptosis (<xref ref-type="bibr" rid="B27">Doll and Conrad, 2017</xref>). Among the key regulators of lipid metabolism, LPCAT3 and ACSL4 assume critical roles (<xref ref-type="bibr" rid="B46">Hishikawa et al., 2008</xref>; <xref ref-type="bibr" rid="B58">K&#xfc;ch et al., 2014</xref>). They effectively facilitate ferroptosis by incorporating PUFAs into cellular phospholipids, particularly phosphatidylethanolamine. Importantly, the inhibition of ACSL4 and LPCAT3 through gene knockdown have been demonstrated to impede ferroptosis (<xref ref-type="bibr" rid="B60">Lee J-Y. et al., 2021</xref>). In a study by Doll S et al. (<xref ref-type="bibr" rid="B29">Doll et al., 2017</xref>), it is observed that ACSL4 exhibits preferential expression in a subset of basal-like BC cell lines. Additionally, ACSL4 expression closely correlates with the sensitivity of RSL3. RSL3 is a potent inducer of ferroptosis.</p>
</sec>
<sec id="s2-5">
<title>2.5 FSP1 and CoQ10</title>
<p>Doll S et al. (<xref ref-type="bibr" rid="B28">Doll et al., 2019</xref>), have discovered that ferroptosis inhibitor protein 1 (FSP1), previously recognized as AIFM2, serves as a formidable factor in conferring resistance against ferroptosis. Importantly, their findings reveal that FSP1&#x2019;s protective influence operates autonomously from the GSH-GPX4 pathway. Coenzyme Q10 (CoQ10), often referred to as ubiquinone, is a lipid-soluble antioxidant with significant roles within the cell. One of its primary functions is to actively engage in cellular energy production, particularly by facilitating electron transport along the cellular respiratory chain within mitochondria (<xref ref-type="bibr" rid="B42">Hargreaves et al., 2020</xref>). Within the FSP1-NAD(P)H pathway, CoQ10 plays a pivotal role by directly intercepting lipid peroxyl radicals, thereby diminishing lipid peroxides. In this process, FSP1 acts as a catalyst, facilitating the regeneration of CoQ10&#xa0;at the cost of NAD(P)H (<xref ref-type="bibr" rid="B9">Bersuker et al., 2019</xref>). Yang J et al. (<xref ref-type="bibr" rid="B119">Yang J. et al., 2022</xref>), effectively countered ferroptosis resistance mediated by FSP1 in TNBC by encapsulating rosuvastatin within silk fibroin nanoparticles, denoted as Cu-SF(RSV) NPs. This approach resulted in the inhibition of TNBC progression.</p>
</sec>
</sec>
<sec id="s3">
<title>3 Compounds as ferroptosis regulator in breast cancer</title>
<sec id="s3-1">
<title>3.1 Natural bioactive compounds</title>
<p>Natural plants are a rich source of bioactive components and extracts that exhibit diverse biological activities, including anti-cancer properties (<xref ref-type="bibr" rid="B41">Haque et al., 2021</xref>), antioxidative effects, immunomodulation (<xref ref-type="bibr" rid="B143">Zhou X. et al., 2022</xref>), and antibacterial actions (<xref ref-type="bibr" rid="B99">Tian et al., 2022</xref>). Consequently, they hold tremendous potential for the treatment of various diseases. However, the precise mechanisms and targets involved in ferroptosis remain poorly understood. Recent research has highlighted the potential of numerous natural plant compounds as modulators of ferroptosis, offering a promising avenue for their anti-cancer effects (<xref ref-type="bibr" rid="B137">Zhang S. et al., 2021</xref>; <xref ref-type="bibr" rid="B140">Zhao et al., 2022</xref>). Phytochemicals can be categorized into different groups based on their chemical composition, including polyphenols, terpenoids, alkaloids, flavonoids, and others (<xref ref-type="bibr" rid="B1">Akhtar et al., 2020</xref>). (The natural compounds are summarized in <xref ref-type="table" rid="T1">Table 1</xref>, and the mechanism of action of them are summarized in <xref ref-type="fig" rid="F1">Figure 1</xref>.)</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Phytochemicals that exert anti-breast cancer effects by targeting ferroptosis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Serial number</th>
<th align="center">Phytochemical compounds</th>
<th align="center">Class of compounds</th>
<th align="center">Source</th>
<th align="center">Effects and mechanisms</th>
<th align="center">Cell/Animal models</th>
<th align="center">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="center">1</td>
<td rowspan="2" align="center">Curcumin</td>
<td rowspan="2" align="center">Polyphenols (phenolic acid)</td>
<td rowspan="2" align="center">Turmeric</td>
<td align="center">&#x2191;HO-1</td>
<td align="center">MCF-7, MDA-MB-231</td>
<td align="center">
<xref ref-type="bibr" rid="B65">Li et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">&#x2191;SLC1A5</td>
<td align="center">MDA-MB-453, MCF-7; BALB/c nude mice</td>
<td align="center">
<xref ref-type="bibr" rid="B11">Cao et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">2</td>
<td rowspan="2" align="center">Robustaflavone 7.5&#x2032;&#x27;-dimethyl ether</td>
<td rowspan="2" align="center">Polyphenols (Flavonoids)</td>
<td rowspan="2" align="center">S. trichoclada</td>
<td align="center">&#x2193;ACSL4</td>
<td align="center">MCF-7</td>
<td align="center">
<xref ref-type="bibr" rid="B112">Xie et al. (2022b)</xref>
</td>
</tr>
<tr>
<td align="center">&#x2191;VDAC2, &#x2193;Nedd4</td>
<td align="center">MCF-7</td>
<td align="center">
<xref ref-type="bibr" rid="B111">Xie et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">Quercetin</td>
<td align="center">Polyphenols (Flavonoids)</td>
<td align="center">Fruits and vegetables, such as onions, grapes and leafy greens</td>
<td align="center">&#x2191;TFEB, &#x2193;lysosom, l degradation of ferritin</td>
<td align="center">MCF-7, MDA-231</td>
<td align="center">
<xref ref-type="bibr" rid="B3">An and Hu (2022)</xref>
</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">Levistilide A</td>
<td align="center">Polyphenols (Flavonoids)</td>
<td align="center">Chuanxiong rhizoma</td>
<td align="center">&#x2193;NRF-2/HO-1 Signaling Pathway</td>
<td align="center">MCF-7, MDA-MB-231</td>
<td align="center">
<xref ref-type="bibr" rid="B52">Jing et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">Gallic acid</td>
<td align="center">Polysaccharides</td>
<td align="center">A variety of plants, such as gallnuts, watercress</td>
<td align="center">&#x2193;GPX4</td>
<td align="center">MDA-MB-231</td>
<td align="center">
<xref ref-type="bibr" rid="B55">Khorsandi et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">Glycyrrhetinic acid</td>
<td align="center">Terpenoids (Triterpenoids)</td>
<td align="center">Licorice</td>
<td align="center">&#x2191;NAPDH oxidase activity, &#x2191;iNOS expression, &#x2193;glutathione level, &#x2193;GPX4, &#x2193;SLC7A11</td>
<td align="center">MDA-MB-231, MCF-10A, BT-549</td>
<td align="center">
<xref ref-type="bibr" rid="B106">Wen et al. (2021a)</xref>
</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">Isoliquiritin</td>
<td align="center">Terpenoids (Triterpenoids)</td>
<td align="center">Liquorice</td>
<td align="center">&#x2193;GPX4, &#x2193;SLC7A11</td>
<td align="center">MDA-MB-231, MCF-7, BALB/c nude mice</td>
<td align="center">
<xref ref-type="bibr" rid="B101">Wang et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">Eupaformosanin</td>
<td align="center">Terpenoids (Sesquiterpenoids)</td>
<td align="center">Eupatorium cannabinum linn</td>
<td align="center">&#x2193;SLC7A11</td>
<td align="center">MDA-MB-231, MDA-MB-468; BALB/c nude mice</td>
<td align="center">
<xref ref-type="bibr" rid="B104">Wei et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">Arnicolide D</td>
<td align="center">Terpenoids (Sesquiterpenoids)</td>
<td align="center">Centipeda minima</td>
<td align="center">&#x2193;GPX4</td>
<td align="center">MDA-MB-231, MDA-MB-468</td>
<td align="center">
<xref ref-type="bibr" rid="B105">Wen et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">Dihydroisotanshinone I</td>
<td align="center">Terpenoids (Diterpenoids)</td>
<td align="center">Salvia miltiorrhiza Bunge</td>
<td align="center">&#x2193;GPX4</td>
<td align="center">MCF-7, MDA-MB-231, BALB/c nude mice</td>
<td align="center">
<xref ref-type="bibr" rid="B67">Lin et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">11</td>
<td align="center">Dihydroartemisinin</td>
<td align="center">Terpenoids (Monoterpenoids)</td>
<td align="center">Artemisia annua</td>
<td align="center">IRP-IRE signaling, &#x2191;lysosomal degradation of ferritin</td>
<td align="center">MDA-MB-453, MCF7</td>
<td align="center">
<xref ref-type="bibr" rid="B13">Chen et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="center">12</td>
<td align="center">DMOCPTL</td>
<td align="center">Terpenoids (Sesquiterpenoids)</td>
<td align="center">Tanacetum parthenium</td>
<td align="center">&#x2193;GPX4 (induce ubiquitination)</td>
<td align="center">MDA-MB-231, SUM159, BT574, 4T1, Hs578T, MDA-MB-468</td>
<td align="center">
<xref ref-type="bibr" rid="B24">Ding et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">13</td>
<td align="center">Lycium barbarum polysaccharide</td>
<td align="center">Polysaccharides</td>
<td align="center">Barbarum</td>
<td align="center">&#x2193; SLC7A11, &#x2193;GPX4</td>
<td align="center">MCF-7, MDA-MB-231</td>
<td align="center">
<xref ref-type="bibr" rid="B32">Du et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">14</td>
<td align="center">Red ginseng polysaccharide</td>
<td align="center">Polysaccharides</td>
<td align="center">Red ginseng</td>
<td align="center">&#x2193;GPX4</td>
<td align="center">MDA-MB-231</td>
<td align="center">
<xref ref-type="bibr" rid="B131">Zhai et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">15</td>
<td align="center">&#x3b1;-eleostearic acid</td>
<td align="center">Fatty acid compounds (Linolenic acid)</td>
<td align="center">Vernicia fordii</td>
<td align="center">Triggering ACSL1-dependent increase in lipid hydroperoxides</td>
<td align="center">MDA-MB-468, MDA-MB-231, BT-549, BT-20, Hs-578T; NSG mice</td>
<td align="center">
<xref ref-type="bibr" rid="B8">Beatty et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">16</td>
<td align="center">Tetrandrine citrate</td>
<td align="center">Pyrrole alkaloids</td>
<td align="center">Radix Stephaniae Tetrandrae</td>
<td align="center">&#x2191;NCOA4-mediated ferritin phagocytosis, &#x2193;FTH1, &#x2193;GPX4</td>
<td align="center">MDA-MB-231, MCF7</td>
<td align="center">
<xref ref-type="bibr" rid="B128">Yin et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">17</td>
<td align="center">Alloimperatorin</td>
<td align="center">Benzopyran (Coumarins)</td>
<td align="center">Angelica dahurica</td>
<td align="center">&#x2193;GPX4, &#x2193;SLC7A11</td>
<td align="center">MCF-10A, MDA-MB-231, MCF-7</td>
<td align="center">
<xref ref-type="bibr" rid="B135">Zhang et al. (2022b)</xref>
</td>
</tr>
<tr>
<td align="center">18</td>
<td align="center">Polyphyllin III</td>
<td align="center">Glycosides (Saponins)</td>
<td align="center">Chinese Clematis</td>
<td align="center">&#x2193;KLF4, &#x2191;ACSL4, &#x2191;SLC7A11</td>
<td align="center">MDA-MB-231, HS578T, MCF-7, T47D, HBL-100, BT549, MDA-MB-453, NHFB</td>
<td align="center">
<xref ref-type="bibr" rid="B144">Zhou et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">19</td>
<td align="center">Formosanin C</td>
<td align="center">Glycosides (Saponins)</td>
<td align="center">Rhizoma Paridis</td>
<td align="center">&#x2193;GPX4, &#x2193;SLC7A11, &#x2191;LC3, &#x2191;ferritinophagy</td>
<td align="center">MCF-7, MDA-MB-231</td>
<td align="center">
<xref ref-type="bibr" rid="B14">Chen et al. (2022b)</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<bold>&#x2191;, promote; &#x2193;, inhibit;</bold> ACSL1, Acyl-CoA Synthetase Long-Chain Family Member 1; ACSL4, Acyl-CoA Synthetase Long-Chain Family Member 4; FPN, ferroportin; FTH1, ferritin heavy chain 1; FTL, ferritin light chain; GSH, glutathione; GSSG, glutathione disulfide; HO-1, heme oxygenase-1; IRP, iron regulatory protein; LAMP-1, Lysosomal-associated membrane protein 1; LPCAT3, Lysophosphatidylcholine acyltransferase 3; KLF4, Kruppel-like factor 4; NADPH, nicotinamide adenine dinucleotide phosphate, reduced form; NCOA4, nuclear receptor coactivator 4; NOS, nitric oxide synthase; NRF-2, nuclear factor erythroid-2-related factor 2; NEDD4L, Neural precursor cell Expressed Developmentally Downregulated 4-Like; PL-OOH, peroxyl radical lipid hydroperoxide; PL-OH, phospholipid alcohol; PUFA, polyunsaturated fatty acid; PUFA-CoA, Polyunsaturated Fatty Acid-Coenzyme A; PUFA-PL, Polyunsaturated Fatty Acid-Phospholipid; SLC7A11, Solute Carrier Family 7 Member 11 (xcT); SLC3A2, Solute Carrier Family 3 Member 2; TFEB, Transcription Factor EB; VDAC2, Voltage-Dependent Anion Channel 2; TF-TFe, Transcription Factor Transferrin Enhancer.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Ferroptosis induced by phytochemicals in breast cancer cells. Abbreviation: AD, Arnicolide D; All, Alloimperatorin; Cur, Curcumin; DAT, Dihydroartemisinin; DMO, DMOCPTL; DT, Dihydroisotanshinone I; Eup, Eupaformosanin; FC, Formosanin C; GA1, Gallic acid; GA2, Glycyrrhetinic acid; ISO, Isoliquiritin; LA, Levistilide A; LBP, Lycium barbarum polysaccharide; PPIII, Polyphyllin III; Que, Quercetin; RF-A, Robustaflavone 7.5&#x2032;&#x27;-dimethyl ether; RGP, Red ginseng polysaccharide; TC, Tetrandrine citrate; &#x3b1;ESA, &#x3b1;-eleostearic acid; ACSL1, Acyl-CoA Synthetase Long-Chain Family Member 1; ACSL4, Acyl-CoA Synthetase Long-Chain Family Member 4; FTH1, ferritin heavy chain 1; FTL: ferritin light chain; GSH: Glutathione; GSSG: Glutathione disulfide; HO-1: heme oxygenase-1; IRP: Iron regulatory protein; LAMP-1, Lysosomal-associated membrane protein 1; LPCAT3, Lysophosphatidylcholine acyltransferase 3; NCOA4, nuclear receptor coactivator 4; Nrf-2, nuclear factor erythroid-2-related factor 2; NEDD4L, Neural precursor cell Expressed Developmentally Downregulated 4-Like; PL-OOH, Peroxyl radical lipid hydroperoxide; PL-OH, Phospholipid alcohol; PUFA, Polyunsaturated Fatty Acid; PUFA-CoA, Polyunsaturated Fatty Acid-Coenzyme A; PUFA-PL, Polyunsaturated Fatty Acid-Phospholipid; SLC7A11, Solute Carrier Family 7 Member 11 (xcT); SLC3A2: Solute Carrier Family 3 Member 2; TFEB, Transcription Factor EB; VDAC2, Voltage-Dependent Anion Channel 2; TF-TFe, Transcription Factor Transferrin Enhancer.</p>
</caption>
<graphic xlink:href="fphar-14-1243286-g001.tif"/>
</fig>
<sec id="s3-1-1">
<title>3.1.1 Polyphenols</title>
<p>Polyphenols encompass a diverse group of organic compounds characterized by multiple phenolic groups (-OH) arranged in benzene rings or analogous structures. This category includes various bioactive plant metabolites like phenolic acids, flavonoids, lignans, anthocyanins, and others (<xref ref-type="bibr" rid="B107">Williamson, 2017</xref>; <xref ref-type="bibr" rid="B21">Cory et al., 2018</xref>).</p>
<p>Curcumin is the principal active compound derived from the underground rhizome of the traditional Chinese medicine Curcuma longa. It belongs to the phenolic acid subgroup within the polyphenol family. Studies by Cao, X et al. (<xref ref-type="bibr" rid="B11">Cao et al., 2022</xref>), have demonstrated that Curcumin induces ferroptosis in breast cancer cells by upregulating the expression of SLC1A5. The inhibition of SLC1A5 in MDA-MB-453 and MCF-7 cells resulted in decreased glutamine uptake, increased levels of lipid ROS, accumulation of lipid peroxidation products, and elevated intracellular Fe<sup>2&#x2b;</sup> levels. Similarly, Li, R et al. (<xref ref-type="bibr" rid="B65">Li et al., 2020</xref>), discovered that curcumin upregulates several ferroptosis-related target genes involved in REDOX regulation, particularly HO-1. The effective attenuation of curcumin-induced ferroptosis in breast cancer cells is achieved by inhibiting HO-1 using the specific inhibitor Zinc Protoporphyrin (ZnPP). This is demonstrated by a notable decrease in lipid peroxidation and an elevation in intracellular glutathione levels.</p>
<p>Xie Y et al. (<xref ref-type="bibr" rid="B112">Xie et al., 2022b</xref>), isolated various diflavone compounds with distinct structural forms from Seladella. Among them, Robustaflavone 7,5&#x2033;-dimethyl ether (RF-A) exhibite the ability to induce ferroptosis in breast cancer cells by downregulating ACSL4 protein expression. Furthermore, RF-A promoted ferroptosis by upregulating VDAC2 protein expression and suppressing the expression of NEDD4 E3 ubiquitin ligase, leading to lipid peroxidation and ROS production (<xref ref-type="bibr" rid="B111">Xie et al., 2021</xref>).</p>
<p>Quercetin, another polyphenolic compound found in several plants and fruits such as onions, grapes, apples, and leafy green vegetables. It can activate the transcription of transcription factor EB (TFEB) in BC cells. This, in turn, stimulates the lysosomal degradation of ferritin, resulting in increased intracellular iron ion concentration and the induction of ferroptosis. (<xref ref-type="bibr" rid="B3">An and Hu, 2022</xref>).</p>
<p>Levistilide A (LA) is an active compound derived from Ligusticum wallichii, which has been shown to significantly enhance ROS-induced ferroptosis by activating the Nrf2/HO-1 signaling pathway (<xref ref-type="bibr" rid="B52">Jing et al., 2022</xref>).</p>
<p>Gallic acid (GA1) is a naturally occurring phenolic acid compound widely found in nature (<xref ref-type="bibr" rid="B2">Al Zahrani et al., 2020</xref>). Extensive research has revealed the remarkable antioxidant and anticancer properties of GA1. Alkyl gallate, a derivative of GA1, is commonly employed as an antioxidant additive in various food products (<xref ref-type="bibr" rid="B26">Dodo et al., 2008</xref>). A study has shown that the combination of low-level laser irradiation and GA1 treatment has been shown to induce ferroptosis in MDA-MB-231 cells by reducing GPX4 activity and promoting lipid peroxidation (<xref ref-type="bibr" rid="B55">Khorsandi et al., 2020</xref>).</p>
</sec>
<sec id="s3-1-2">
<title>3.1.2 Terpenoids</title>
<p>Terpenes are natural compounds composed of multiple isoprene units (C5H8). Terpenoids can be classified into different groups based on the number of ring structures they contain. Terpenoids can be categorized into different groups based on the number of ring structures they possess. Monomeric terpenoids consist of a single ring structure, while diterpenoids and triterpenoids are characterized by two and three ring structures respectively (<xref ref-type="bibr" rid="B118">Yang and Dou, 2010</xref>). Each of these classes has distinct structures and biological activities.</p>
<p>Glycyrrhetinic acid (GA2), also known as 18-&#x3b2;-glycyrrhetinic acid, is the primary active compound derived from licorice. It exhibits a wide range of anticancer activities in various types of cancer. The cytotoxic and antitumor properties of GA2 are attributed to the presence of triterpene functional groups in its structure, namely, carboxylic acid (-COOH) and hydroxyl (-OH) groups (<xref ref-type="bibr" rid="B86">Roohbakhsh et al., 2016</xref>; <xref ref-type="bibr" rid="B51">Hussain et al., 2021</xref>). GA2 has been shown to induce the production of reactive oxygen species (superoxide and hydroxyl radicals) by activating NADPH oxidase and iNOS. Additionally, it reduces the antioxidant capacity of cells by down-regulating SLC7A11 expression and inhibiting GPX4. These actions subsequently promote lipid peroxidation mediated by reactive oxygen/nitrogen species (ROS/RNS) and trigger ferroptosis (<xref ref-type="bibr" rid="B106">Wen Y. et al., 2021</xref>).</p>
<p>Isoliquiritin (ISO) is a triterpenoid compound derived from licorice. Administration of ISO results in elevated levels of intracellular Fe<sup>2&#x2b;</sup>, ROS, and malondialdehyde (MDA). Concurrently, it reduces the levels of GSH and the relative protein expression of GPX4 and xCT. It is proposed that ISO regulates ferroptosis by potentially inhibiting NF-&#x3ba;B signaling (<xref ref-type="bibr" rid="B101">Wang et al., 2023</xref>).</p>
<p>Eupaformosin is a sesquiterpene lactone compound isolated from Eupatorium cannabinum. <italic>In vitro</italic> and <italic>in vivo</italic> studies have demonstrated that eupaformosin induces ferroptosis by promoting the ubiquitination of mutant p53. p53 is a protein involved in cell cycle regulation and tumor suppression (<xref ref-type="bibr" rid="B104">Wei et al., 2022</xref>).</p>
<p>Arnicolide D is a sesquiterpenoid compound extracted from Centipeda minima, a traditional Chinese medicinal plant. Dihydroisotanshinone I is extracted from the dried root of Salvia miltiorrhiza. Both of them can activate ferroptosis by increasing the accumulation of Fe<sup>2&#x2b;</sup> and MDA while suppressing the expression of GPX4<sup>[71 72]</sup>.</p>
<p>Dihydroartemisinin (DAT), an active metabolite derived from artemisinin and its derivatives (ARTs), has gained significant recognition as an effective drug for the treatment of malaria in clinical practice. DAT demonstrates enhanced bioavailability when compared to its natural counterpart. However, DAT has recently garnered increasing attention for its potential anticancer activity in addition to its antimalarial properties. Researchers have been intrigued by the promising anticancer effects exhibited by DAT, leading to a growing interest in exploring its therapeutic applications in the field of oncology (<xref ref-type="bibr" rid="B23">Dai et al., 2021</xref>). DAT has the ability to induce the degradation of ferritin through lysosomal pathways, consequently impacting iron homeostasis regulated by the iron regulatory protein/iron-responsive element (IRP/IRE) system. This process leads to an increase in the levels of free iron within cells, rendering them more susceptible to ferroptosis (<xref ref-type="bibr" rid="B13">Chen G-Q. et al., 2020</xref>).</p>
<p>DMOCPTL is a derivative of the natural product parthenolide found in plants like feverfew. It induces ferroptosis by ubiquitinating GPX4 (<xref ref-type="bibr" rid="B24">Ding et al., 2021</xref>). This process leads to the degradation of GPX4 and subsequent disruption of cellular antioxidant defense mechanisms.</p>
</sec>
<sec id="s3-1-3">
<title>3.1.3 Other classes of natural compounds</title>
<p>There are other various classes of compounds that exhibit different effects on ferroptosis. These include two polysaccharides, one alkaloid, one Benzopyran (Coumarins), one Fatty acid compound (linolenic acid), and one Glycoside (Saponins).</p>
<p>Lycium barbarum polysaccharide (LBP) is extracted from the fruit of Chinese medicine Lycium barbarum. LBP induced ferroptosis by reducing the expression levels of SLC7A11 and GPX4 (<xref ref-type="bibr" rid="B32">Du et al., 2022</xref>).</p>
<p>Red ginseng polysaccharide (RGP) is one of the main active ingredients extracted from red ginseng. Similar to Lycium barbarum polysaccharide, red ginseng polysaccharide induced ferroptosis by reducing GPX4 expression. And the overexpression of GPX4 in TNBC cells would make cancer cells resistant to RGP (<xref ref-type="bibr" rid="B131">Zhai et al., 2022</xref>).</p>
<p>Alpha eleostearic acid (&#x3b1;ESA) is extracted from tung seed of conjugated linoleic acid ester (<xref ref-type="bibr" rid="B22">Cui et al., 2018</xref>). &#x3b1;ESA was found to induce ferroptosis <italic>in vitro</italic> by triggering an ACSL1-dependent increase in lipid hydroperoxides. At the same time, they administered tung oil to BC mice by gavage and found that tung oil significantly inhibited tumor growth. Gene sequencing of mice revealed a significant upregulation of ferroptosis-related genes, indicating that the inhibition of tumor growth <italic>in vivo</italic> was associated with cell death caused by &#x3b1;ESA <italic>in vitro</italic> (<xref ref-type="bibr" rid="B8">Beatty et al., 2021</xref>).</p>
<p>Tetrandrine citrate (TetC) is a new tetrandrine salt with high water solubility, which can be extracted from the traditional Chinese medicine Tetrandrine. It drove BC cell ferroptosis by activating NCOA4-mediated ferritin phagocytosis and inhibiting GPX4 expression in BC cells (<xref ref-type="bibr" rid="B128">Yin et al., 2022</xref>).</p>
<p>Alloimperatorin is a coumarin compound extracted from Angelica dahurica, a traditional Chinese medicine. It had been found to promote the accumulation of Fe<sup>2&#x2b;</sup>, ROS, and malondialdehyde. Meanwhile, it significantly reduced the mRNA and protein expression levels of SLC7A11 and GPX4. These findings indicate that alloimperatorin induces ferroptosis (<xref ref-type="bibr" rid="B135">Zhang J. et al., 2022</xref>).</p>
<p>Polyphyllin III is a natural saponin extracted from Chinese medicine Paris flos. Zhou Y et al. (<xref ref-type="bibr" rid="B144">Zhou et al., 2021</xref>), found that it exerted a proliferation inhibitory effect on MDA-MB-231 triple-negative BC cells mainly through ACSL4-mediated elevation of lipid peroxidation and induction of ferroptosis. At the same time, the study also found that Polyphyllin III treatment induced a protective upregulation of xcT, a negative regulator of ferroptosis.</p>
<p>Formosanin C (FC) is a diosgenin glycoside extracted from Rhizoma paridis with anticancer activity (<xref ref-type="bibr" rid="B72">Man et al., 2011</xref>). FC induces both autophagy and apoptosis in human lung cancer cells and multiple myeloma cells (<xref ref-type="bibr" rid="B16">Chen P. et al., 2022</xref>; <xref ref-type="bibr" rid="B10">Chu et al., 2023</xref>). Meanwhile, Chen HC et al. (<xref ref-type="bibr" rid="B14">Chen HC. et al., 2022</xref>), identified that FC was a potent ferroptosis inducer in MDA-MB-231 Cells. FC-induced ferroptosis in TNBC is associated with suppressed levels of the FPN, xcT, and GPX4. Ferritinophagy also plays an important role in FC-induced ferroptosis. In addition, FC enhanced the sensitivity of TNBC cells to cisplatin.</p>
</sec>
</sec>
<sec id="s3-2">
<title>3.2 Chemically synthesized compounds</title>
<p>Additionally, several chemosynthetic compounds have demonstrated anti-breast cancer effects through the targeted induction of ferroptosis in BC cells. Notable examples of ferroptosis inducers are erastin and RSL-3, which are widely recognized in the field. Among these are drugs that have already received clinical approval and have been extensively utilized in other fields. Examples include metformin and simvastatin. Furthermore, new chemically synthesized compounds, such as BET inhibitors (BETi), have also shown promising potential in this regard. (The chemically synthesized compounds. are summarized in <xref ref-type="table" rid="T2">Table 2</xref>, and the mechanism of action of them are summarized in <xref ref-type="fig" rid="F2">Figure 2</xref>.)</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Chemically synthesized drugs that act against breast cancer by targeting ferroptosis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Serial number</th>
<th align="center">Name of drug</th>
<th align="center">Drug combination</th>
<th align="center">Effects and mechanisms</th>
<th align="center">Cell/Animal models</th>
<th align="center">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="center">1</td>
<td rowspan="2" align="center">Erastin</td>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2193; SLC7A11, &#x2193;GPX4</td>
<td align="center">MDA-MB-231, CAL-120</td>
<td align="center">
<xref ref-type="bibr" rid="B61">Lee et al. (2021c)</xref>
</td>
</tr>
<tr>
<td align="center">TGF-&#x3b2;1</td>
<td align="center">&#x2193;the formation of the BECN1-SLC7A11 complex</td>
<td align="center">MDA-MB-231, MCF-7</td>
<td align="center">
<xref ref-type="bibr" rid="B49">Huang et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">RSL3</td>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2193; SLC7A11, &#x2193;GPX4</td>
<td align="center">MDA-MB231, CAL-120</td>
<td align="center">
<xref ref-type="bibr" rid="B61">Lee et al. (2021c)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="center">3</td>
<td rowspan="2" align="center">Simvastatin</td>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2193;HMGCR, &#x2193;MVA pathway, &#x2193;GPX4</td>
<td align="center">MDA-MB-231, MCF-7</td>
<td align="center">
<xref ref-type="bibr" rid="B124">Yao et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2193;GPX4</td>
<td align="center">MCF-7, MDA-MB-231</td>
<td align="center">
<xref ref-type="bibr" rid="B35">Elakkad et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="center">4</td>
<td rowspan="3" align="center">Metformin</td>
<td align="center">SAS</td>
<td align="center">&#x2193;SLC7A11, &#x2193;UFM1, &#x2193;UFMylation</td>
<td align="center">MCF-7, T47D, HCC1937, Bcap37, NHFB, HBL-100/nude mice</td>
<td align="center">
<xref ref-type="bibr" rid="B120">Yang et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2191;miR-324-3p, &#x2193;GPX4</td>
<td align="center">MCF-7, MDA-MB-231</td>
<td align="center">
<xref ref-type="bibr" rid="B114">Yan and Bu (2021)</xref>
</td>
</tr>
<tr>
<td align="left"/>
<td align="center">&#x2193;H19, &#x2191;autophagy</td>
<td align="center">MCF-7</td>
<td align="center">
<xref ref-type="bibr" rid="B15">Chen et al. (2022c)</xref>
</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">Lapatinib and Siramesine</td>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2191;transferrin, &#x2193;FPN, &#x2193;SLC7A11, &#x2193;GPX4</td>
<td align="center">MCF-7, MDA-MB-231, SKBr3</td>
<td align="center">
<xref ref-type="bibr" rid="B70">Ma et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">Neratinib</td>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2193;Ferritin, &#x2191;Ferroportin-1</td>
<td align="center">TBCP-1, SKBR3, 67NR, 4T1.2/BALB/C nude mice</td>
<td align="center">
<xref ref-type="bibr" rid="B77">Nagpal et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">Etoposide</td>
<td align="center">erastin</td>
<td align="center">&#x2193;SLC7A11, &#x2193;GPX4, &#x2191;IREB2, &#x2193;FPN1, &#x2191;ACSF2</td>
<td align="center">MCF-7, MCF-10A, MDA-MB-231</td>
<td align="center">
<xref ref-type="bibr" rid="B80">Ozkan and Bakar-Ates (2023a)</xref>
</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">Ketamine</td>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2193;KAT5, &#x2193;GPX4</td>
<td align="center">MCF-7, T47D</td>
<td align="center">
<xref ref-type="bibr" rid="B63">Li et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">Propofol</td>
<td align="center">Doxorubicin/Taxol</td>
<td align="center">&#x2191;p53, &#x2193;GPX4, &#x2193;SLC7A11</td>
<td align="center">MDA-MB-231</td>
<td align="center">
<xref ref-type="bibr" rid="B94">Sun et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">Lidocaine</td>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2191;miR-382-5p, &#x2193;SLC7A11</td>
<td align="center">T47D</td>
<td align="center">
<xref ref-type="bibr" rid="B95">Sun et al. (2021a)</xref>
</td>
</tr>
<tr>
<td align="center">11</td>
<td align="center">Ironomycin (AM5)</td>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2191;the degradation of ferritin in lysosomes</td>
<td align="center">MCF-7, HMLER</td>
<td align="center">
<xref ref-type="bibr" rid="B71">Mai et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="center">12</td>
<td align="center">(&#x2b;)-JQ1</td>
<td align="center">erastin/RSL3/Sorafenib</td>
<td align="center">&#x2193;FTH1, &#x2191;ATG5, &#x2191;LAMP1, &#x2191;ferritinophagy, &#x2193;G9a, &#x2191;SIRT1, &#x2191;DNA methylation</td>
<td align="center">MDA-MB-231, Hs578T, A549, H1299</td>
<td align="center">
<xref ref-type="bibr" rid="B93">Sui et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="center">13</td>
<td align="center">BET inhibitor</td>
<td align="center">BTZ</td>
<td align="center">&#x2191;JNK1/2, &#x2191;ATF2, &#x2191;NRF2</td>
<td align="center">MDA-MB-231, BT-549, HeLa, A549/nude mice</td>
<td align="center">
<xref ref-type="bibr" rid="B102">Wang et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="center">14</td>
<td align="center">Phenazine derivatives</td>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2191;IRP2, &#x2191;TFR1, &#x2193;ferritin</td>
<td align="center">Breast cancer stem cells</td>
<td align="center">
<xref ref-type="bibr" rid="B122">Yang et al. (2022b)</xref>
</td>
</tr>
<tr>
<td align="center">15</td>
<td align="center">CB1 antagonists</td>
<td align="center">erastin/RSL3</td>
<td align="center">&#x2191;SCD1, &#x2191;FADS2</td>
<td align="center">MDA-MB-231, HCC1937</td>
<td align="center">
<xref ref-type="bibr" rid="B64">Li et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="center">16</td>
<td align="center">MI-463</td>
<td align="center">auranofin</td>
<td align="center">&#x2191;HO-1</td>
<td align="center">BT-549, MDA-MB-468, MDA-MB-231, MCF-7, T47D</td>
<td align="center">
<xref ref-type="bibr" rid="B54">Kato et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="center">17</td>
<td align="center">3&#x27;-(nitroisoxazole) spiro [pyrrolidin-3.2&#x2032;-oxindoles]</td>
<td align="center">&#x2014;&#x2014;</td>
<td align="center">&#x2193;MDM2, &#x2193;GPX4</td>
<td align="center">MCF-7</td>
<td align="center">
<xref ref-type="bibr" rid="B69">Liu et al. (2021)</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<bold>&#x2191;, promote; &#x2193;, inhibit;</bold> ACSF2, Acyl-CoA synthetase family member 2; ATF-2, Activating Transcription Factor 2; ATG-5, Autophagy-related gene 5; BRD4, Bromodomain-containing protein 4; FADS2, Fatty Acid Desaturase 2; FPN, ferroportin; FTH1, ferritin heavy chain 1; FTL, ferritin light chain; G9a, Euchromatic Histone Lysine Methyltransferase 2; HMGCR, 3-hydroxy-3-methylglutaryl-CoA, reductase; HO-1, heme oxygenase-1; IREB2, Iron-responsive element-binding protein 2; JNK1/2, c-Jun N-terminal kinase 1/2; KAT5, Lysine acetyltransferase 5; LAMP1, Lysosomal-associated membrane protein 1; MDM2, Mouse Double Minute 2; miR-324-3p, miRNA-324-3p; miR-382-5p, miRNA-382-5p; MVA, mevalonate; NFR-2, Nuclear factor erythroid 2-related factor 2; SCD1, Stearoyl-CoA desaturase 1; SIRT1, Sirtuin 1; TFR1, Transferrin receptor 1; UFM1, Ubiquitin-fold modifier 1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Ferroptosisinduced by Chemically synthesized drugs in breast cancer cells Abbreviation: AM5, Ironomycin; 3d, 3&#x27;-(nitroisoxazole)spiro [pyrrolidin-3.2&#x2032;-oxindoles]; CB1A: CB1 antagonists; Era, Erastin; ETO, Etoposide; BETi, BET inhibitor; LDC, Lidocaine; JQ1, (&#x2b;)-JQ1, bromodomain and extra-terminal motif inhibitor; KT, Ketamine; MF, Metformin; MI-463, Menin-MLL inhibitors; Ner, Neratinib; PD, Phenazine derivatives; PPF, Propofol; RSL-3, Ras-selective lethal 3; Sir and Lap, Lapatinib and Siramesine; SVT, Simvastatin; ATF-2, Activating Transcription Factor 2; ATG-5, Autophagy-related gene 5; BRD4, Bromodomain-containing protein 4; FADS2, Fatty Acid Desaturase 2; FPN, ferroportin; G9a, Euchromatic Histone Lysine Methyltransferase 2; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; HO-1, heme oxygenase-1; JNK1/2, c-Jun N-terminal kinase 1/2; KAT5, Lysine acetyltransferase 5; LAMP1, Lysosomal-associated membrane protein 1; MDM2, Mouse Double Minute 2; miR-324-3p, miRNA-324-3p; miR-382-5p, miRNA-382-5p; NFR-2, Nuclear factor erythroid 2-related factor 2; SCD1, Stearoyl-CoA desaturase 1; SIRT1, Sirtuin 1; UFM1, Ubiquitin-fold modifier 1.</p>
</caption>
<graphic xlink:href="fphar-14-1243286-g002.tif"/>
</fig>
<sec id="s3-2-1">
<title>3.2.1 Erastin and RSL-3</title>
<p>In 2003, Dolma et al. (<xref ref-type="bibr" rid="B30">Dolma et al., 2003</xref>), classic apoptotic features were not found in erastin-induced cell death. Erastin-induced cell death is considered as a novel form of non-apoptotic cell death. Dixon et al. (<xref ref-type="bibr" rid="B25">Dixon et al., 2012</xref>), named erastin-induced cell death as ferroptosis. At the same time, as GSH is an indispensable substrate for the antioxidant effect of GPX4, the activity of GPX4 will also be inhibited (<xref ref-type="bibr" rid="B141">Zhao et al., 2020</xref>). Huang P et al. (<xref ref-type="bibr" rid="B49">Huang et al., 2023</xref>), found that the combination treatment of erastin and TGF-&#x3b2;1 could mediate autophagy-dependent ferroptosis by inducing the formation of the BECN1-SLC7A11 complex. Meanwhile, Lee N et al. (<xref ref-type="bibr" rid="B61">Lee et al., 2021c</xref>), also found that the classical ferroptosis inducer RSL-3 was able to induce the occurrence of ferroptosis in breast cancer cells.</p>
</sec>
<sec id="s3-2-2">
<title>3.2.2 Statins</title>
<p>In recent studies, there is mounting evidence indicating the potential of statins as agents capable of inducing ferroptosis (<xref ref-type="bibr" rid="B124">Yao X. et al., 2021</xref>; <xref ref-type="bibr" rid="B35">Elakkad et al., 2021</xref>; <xref ref-type="bibr" rid="B78">Ning et al., 2021</xref>; <xref ref-type="bibr" rid="B136">Zhang Q. et al., 2022</xref>). Statins are potent inhibitors of HMGCR, which plays a crucial role in controlling cholesterol biosynthesis through the mevalonate pathway (MVA) (<xref ref-type="bibr" rid="B129">Yu et al., 2017</xref>). The mevalonate pathway is involved in the synthesis of selenoproteins, including the active center of GPX4. By inhibiting the mevalonate pathway, statins can regulate ferroptosis by simultaneously suppressing ROS and down-regulating the levels of GPX4 (<xref ref-type="bibr" rid="B124">Yao X. et al., 2021</xref>; <xref ref-type="bibr" rid="B35">Elakkad et al., 2021</xref>). Notably, YAO X et al. (<xref ref-type="bibr" rid="B124">Yao X. et al., 2021</xref>), demonstrated an enhanced therapeutic effect against TNBC by utilizing zwitterionic polymer-coated magnetic nanoparticles (Fe3O4@PCBMA) to deliver the ferroptosis-inducing drug simvastatin (SIM).</p>
</sec>
<sec id="s3-2-3">
<title>3.2.3 Metformin</title>
<p>Metformin is the most widely used oral hypoglycemic drug in clinical practice, which is commonly used to treat type 2 diabetes. In recent years, metformin has been proved to have the effect of cancer treatment and prevention, such as liver cancer, BC, colon cancer, pancreatic cancer and so on (<xref ref-type="bibr" rid="B45">Heckman-Stoddard et al., 2017</xref>). The verification of clinical efficacy of metformin and the exploration of potential mechanisms have become the research hotspots in the field of cancer. Metformin can activate AMPK to inactivate mTOR, thereby reducing cell proliferation and inducing apoptosis and cell cycle arrest (<xref ref-type="bibr" rid="B138">Zhao et al., 2015</xref>; <xref ref-type="bibr" rid="B45">Heckman-Stoddard et al., 2017</xref>). At the same time, metformin can indirectly affect tumorigenesis by affecting insulin levels and inducing energy stress (<xref ref-type="bibr" rid="B82">Pernicova and Korbonits, 2014</xref>). In addition, recent studies have found that metformin can also exert anti-tumor effects by inducing ferroptosis. Yang J et al. (<xref ref-type="bibr" rid="B120">Yang et al., 2021</xref>), found that metformin reduced the protein stability of SLC7A11 by inhibiting its UFMylation process. In addition, metformin could act synergistically when combined with the xc-system inhibitor sulfasalazine. Non-coding RNA are a class of RNA molecules that are widespread in cells and are synthesized during transcription but not translated into proteins. Non-coding RNA can be divided into several subclasses, including long non-coding RNA (lncRNA), microRNA (miRNA), small interfering RNA (siRNA), small nuclear RNA (snRNA) and so on (<xref ref-type="bibr" rid="B114">Yan and Bu, 2021</xref>). Metformin was found to induce ferroptosis via non-coding RNA. In TNBC cells, metformin promoted ferroptosis by up-regulating miR-324-3p expression and targeting GPX4 inhibition (<xref ref-type="bibr" rid="B48">Hou et al., 2021</xref>). Meanwhile, metformin-induced ferroptosis is achieved through the downregulation of lncRNA H19 and the inhibition of autophagy (<xref ref-type="bibr" rid="B15">Chen J. et al., 2022</xref>).</p>
</sec>
<sec id="s3-2-4">
<title>3.2.4 Anti-tumor drugs</title>
<p>Anti-tumor drugs encompass various types, including chemotherapy drugs and targeted drugs. Lapatinib has been approved for the treatment of ErbB-positive BC (<xref ref-type="bibr" rid="B100">Tolaney, 2014</xref>). It functions as a dual tyrosine kinase inhibitor, targeting both ErbB1 and ErbB2 tyrosine kinase receptors (<xref ref-type="bibr" rid="B108">Wood et al., 2004</xref>). On the other hand, siramesine is a sigma-2 receptor ligand originally developed for depression treatment (<xref ref-type="bibr" rid="B44">Heading C. Siramesine H Lundbeck, 2001</xref>). S MA et al. (<xref ref-type="bibr" rid="B70">Ma et al., 2016</xref>), discovered that the combination of siramesine and lapatinib induced ferroptosis by increasing the expression of transferrin and decreasing the expression of ferroportin-1 (FPN1). Meanwile, they found that cystine transport inhibition promotes siramesine and lapatinib-induced cell death.</p>
<p>Neratinib, an irreversible pan-TKI, targets EGFR/HER1, HER2, and HER4 of the ERBB tyrosine kinase family (<xref ref-type="bibr" rid="B83">Rabindran et al., 2004</xref>). It is approved for extended adjuvant therapy in HER2-positive breast cancer as a single agent and in combination with capecitabine for advanced or metastatic disease (<xref ref-type="bibr" rid="B38">Geyer et al., 2006</xref>; <xref ref-type="bibr" rid="B56">Kourie et al., 2017</xref>). In HER2-positive BC cells (TBCP-1) treated with Neratinib, the levels of ferritin and FPN1 increased by 2-fold and 1.6-fold, respectively. Intracellular iron concentration also showed a dose-dependent increase at 72&#xa0;h, as demonstrated by ICP-MS analysis. These findings indicated the proferroptosis activity of neratinib in HER2-positive BC cells (<xref ref-type="bibr" rid="B77">Nagpal et al., 2019</xref>).</p>
<p>Etoposide is a semi-synthetic derivative of podophyllotoxin. It is commonly used to treat malignant tumors such as leukemia and lymphoma (<xref ref-type="bibr" rid="B75">Meresse et al., 2004</xref>). Its primary mechanism of action involves inhibiting cell growth by forming a complex with topoisomerase II (<xref ref-type="bibr" rid="B6">Baldwin and Osheroff, 2005</xref>). A recent study (<xref ref-type="bibr" rid="B80">Ozkan and Bakar-Ates, 2023a</xref>) discovered that the combination of etoposide and erastin synergistically induced ferroptosis. This effect may be achieved through the inhibition of glutathione peroxidase activity and alterations in the expression of the ferroptosis regulatory protein IREB2 and FPN1. IREB2 is a protein that responds to changes in intracellular iron levels by binding to IRE, which regulate the expression of ferritin and TFR.</p>
</sec>
<sec id="s3-2-5">
<title>3.2.5 Narcotic drugs</title>
<p>Recent studies have unveiled numerous non-anesthetic effects of anesthetics, including anti-tumor activity, anti-inflammatory properties, and even an antidepressant effect (<xref ref-type="bibr" rid="B12">Caracas et al., 2009</xref>; <xref ref-type="bibr" rid="B66">Li et al., 2019</xref>; <xref ref-type="bibr" rid="B89">Smith-Apeldoorn et al., 2022</xref>). Among them, propofol stands out as one of the most commonly used intravenous anesthetics in clinical practice. Several investigations have indicated that the administration of propofol during surgery improved the prognosis of BC patients compared to inhaled anesthetics (<xref ref-type="bibr" rid="B125">Yap et al., 2019</xref>). Sun C et al. (<xref ref-type="bibr" rid="B94">Sun et al., 2022</xref>), discovered that propofol, propofol injection emulsion, and phosphopropofol disodium significantly enhanced the antitumor effects of doxorubicin and paclitaxel while inducing changes associated with ferroptosis. In MDA-MB-231 cells, propofol may promote ferroptosis through the p53-SLC7A11-GPX4 pathway.</p>
<p>Ketamine is a rapid-acting anesthetic widely utilized in surgery since 1970, possessing potential anti-tumor activity (<xref ref-type="bibr" rid="B34">Dundee et al., 1970</xref>). Its anti-cancer properties have been demonstrated in various cancer models (<xref ref-type="bibr" rid="B33">Duan et al., 2019</xref>; <xref ref-type="bibr" rid="B43">He et al., 2021</xref>). In a study by Li H et al. (<xref ref-type="bibr" rid="B63">Li et al., 2021</xref>), edu-positive breast cancer cells were treated with ketamine, resulting in a significant increase in ferroptosis markers. Ketamine inhibited the expression of GPX4 by attenuating KAT5 in the GPX4 promoter region. This attenuation led to the inhibition of histone H3 lysine 27 acetylation (H3K27ac) and RNA polymerase II (RNA pol II) enrichment, ultimately suppressing the expression of GPX4.</p>
<p>Lidocaine is a local anesthetic extracted from cocaine and widely used in clinical practice. Through the analysis of clinical samples from ovarian and breast cancer patients, Sun P et al. (<xref ref-type="bibr" rid="B95">Sun D. et al., 2021</xref>), discovered a downregulation of miR-382-5p expression, while observing an upregulation of SLC7A11 expression. Lidocaine downregulated SLC7A11 expression by enhancing miR-382-5p in the BC cells.</p>
</sec>
<sec id="s3-2-6">
<title>3.2.6 Other novel compounds</title>
<p>Salinomycin is a broad-spectrum antibiotic with antibacterial effects. Mai T et al. (<xref ref-type="bibr" rid="B71">Mai et al., 2017</xref>), found a synthetic derivative of salinomycin, which they named ironomycin (AM5). AM5 exhibited a more potent and selective activity against breast CSCs <italic>in vitro</italic> and <italic>in vivo</italic>, accumulates and sequesters iron in lysosomes. In response to the ensuing cytoplasmic depletion of iron, cells triggered the degradation of ferritin in lysosomes, leading to further iron loading in this organelle.</p>
<p>BETi belong to a class of compounds that effectively inhibit the BET protein family. By competing with acetylated histones for binding to BET proteins, BET inhibitors reduce oncogene expression, thereby inhibiting tumor cell proliferation and promoting apoptosis (<xref ref-type="bibr" rid="B4">Andrieu et al., 2016</xref>). The BET protein family comprises BRD2, BRD3, BRD4, and BRDT (<xref ref-type="bibr" rid="B88">Shi et al., 2014</xref>). Prominent examples of BETi include JQ1 and I-BET. Sui S et al. (<xref ref-type="bibr" rid="B93">Sui et al., 2019</xref>), discovered that (&#x2b;)-JQ1 inhibited BRD4 expression by suppressing the histone methylase G9a or activating the histone deacetylase SIRT1. This inhibition of BRD4 expression enhanced the expression of ATG5 and LAMP1, leading to the induction of ferritin phagocytosis. Wang L et al. (<xref ref-type="bibr" rid="B102">Wang et al., 2021</xref>), observed that BEi JQ1 and I-BET 151 (I-BET) activated the JNK/ATF2 pathway in MDA-MB-231 breast cancer cells. Activation of ATF2 by BETi blocks BETi-induced ferroptosis in cancer cells by upregulating NRF2 expression. These findings suggested that inhibiting ATF2 or NRF2 may enhance BET-induced ferroptosis, thereby augmenting the anticancer effects of BETi.</p>
<p>Phenazine derivatives belong to a substantial class of planar nitrogen-containing heterocyclic compounds. The key core structure is the pyrazine ring with two cyclic benzenes (1,4-diazabenzene) (<xref ref-type="bibr" rid="B115">Yan et al., 2021</xref>). These compounds exhibit diverse biological activities, including antimicrobial, antidepressant, anticancer, and other pharmacological effects (<xref ref-type="bibr" rid="B37">Gao et al., 2013</xref>; <xref ref-type="bibr" rid="B57">Krishnaiah et al., 2018</xref>). Yang Y et al. (<xref ref-type="bibr" rid="B122">Yang Y. et al., 2022</xref>), conducted a screening of phenazine library compounds targeting breast cancer stem cells and identified three compounds (CPUL119, CPUL129, and CPUL149). These compounds effectively accumulate and sequester iron in lysosomes through their interaction with iron. Additionally, they regulate the expression of proteins involved in iron transport and storage (IRP2, TFR1, ferritin), triggering ferroptosis.</p>
<p>CB1 antagonists block the interaction of endocannabinoids, such as the endogenous CB1 agonist anandamide, with CB1 receptors by binding to the CB1 receptor. Li P et al. (<xref ref-type="bibr" rid="B64">Li et al., 2022</xref>), identified that CB1 antagonists regulated sensitivity of TNBC cells to ferroptosis by regulating SCD1-and FADS2-dependent fatty acid metabolism. Some CB1 antagonists, such as rimonabant, have been investigated in clinical trials for obesity, metabolic diseases, and drug abuse. However, rimonabant is no longer approved for medical use due to its psychiatric side effects, such as anxiety and depression (<xref ref-type="bibr" rid="B20">Christensen et al., 2007</xref>).</p>
<p>MI-463 is menin-mixed-lineage leukemia inhibitors, unexpectedly inducing the ferroptotic cell death of several cancer cell lines. MI-463 in combination with auranofin, a thioredoxin reductase inhibitor, induced ferroptosis through upregulation of HO-1 (<xref ref-type="bibr" rid="B54">Kato et al., 2020</xref>).</p>
<p>Furthermore, there are other compounds, such as nitroisoxazole-containing spiro [pyrrolidin-oxindole] derivatives (<xref ref-type="bibr" rid="B69">Liu et al., 2021</xref>). which have been identified as novel dual inhibitors of GPX4 and MDM2.</p>
</sec>
</sec>
</sec>
<sec id="s4">
<title>4 Conclusion and perspectives</title>
<p>Ferroptosis, as a form of regulated cell death, offers a promising approach for cancer treatment with multiple regulatory pathways. This review focuses on natural phytochemicals and chemosynthetic compounds that target ferroptosis in BC, summarizing their mechanisms of action both <italic>in vitro</italic> and <italic>in vivo</italic>. Among the various targets, GPX4 and xc-T have emerged as common targets for compound-induced ferroptosis. Some compounds induce ferroptosis also by affecting ferritin autophagy and lipid peroxidation. Transcription factors (P53, NRF2) and non-coding RNA are identified as potential key regulators of compound-induced ferroptosis.</p>
<p>In addition, this review highlights the potential synergistic effects of combining compounds with classical ferroptosis inducers (erastin/RSL3/SAS) or antitumor drugs (Sorafenib/Doxorubicin/paclitaxel) <sup>[99,113 118,123 127,133]</sup>. For example, Ozkan, E. et al. (<xref ref-type="bibr" rid="B81">Ozkan and Bakar-Ates, 2023b</xref>), investigated the combination therapy of etoposide and erastin, demonstrating that ferroptosis induction enhances the anticancer effect of etoposide at lower doses, thereby minimizing side effects on normal tissues. The relationship between ferroptosis and tumor immunity has also gained recognition, with evidence suggesting its involvement in T-cell-mediated antitumor immunity and its impact on the efficacy of cancer immunotherapy (<xref ref-type="bibr" rid="B103">Wang et al., 2019</xref>). Recent studies have shown that combining GPX4 inhibitors with immune checkpoint blockade (anti-PD-1) exhibits superior effectiveness in inhibiting breast tumor growth compared to monotherapy (<xref ref-type="bibr" rid="B117">Yang et al., 2023b</xref>). Notably, the induction of ferroptosis, either directly or indirectly, holds promise as a combinatorial strategy to enhance anti-PD-1/PD-L1 immunotherapy (<xref ref-type="bibr" rid="B96">Sun LL. et al., 2021</xref>). The combination of different drugs to achieve improved efficacy and reduced toxicity represents a potential direction for the development of ferroptosis-targeting drugs in the future.</p>
<p>Despite the rapid progress in understanding the mechanisms of ferroptosis in BC, its clinical application still faces challenges. Ferroptosis occurs not only in cancer cells but also in normal tissues, raising concerns about potential complications upon the use of ferroptosis-inducing agents in humans (<xref ref-type="bibr" rid="B92">Sui et al., 2022</xref>). Erastin, a classical ferroptosis inducer, has been shown to alter blood index values and cause mild cerebral infarction and increased glomerular volume in animal experiments (<xref ref-type="bibr" rid="B139">Zhao et al., 2021</xref>). Additionally, erastin&#x2019;s poor water solubility and unstable metabolism <italic>in vivo</italic> make it unsuitable for direct <italic>in vivo</italic> use (<xref ref-type="bibr" rid="B141">Zhao et al., 2020</xref>). Although some approved drugs such as metformin and propofol have been shown to induce ferroptosis, their primary therapeutic roles lie outside of ferroptosis induction, and the activation of other pathways by these drugs may lead to significant side effects. It&#x27;s important to note that current ferroptosis research primarily relies on cell and animal experiments, which may differ from human physiological conditions (<xref ref-type="bibr" rid="B137">Zhang S. et al., 2021</xref>). At present, there is no drug study on ferroptosis in BC in the clinical trial registration website. Therefore, caution should be exercised when extrapolating findings from cell and animal studies to human applications. In recent times, nanoparticles have found increasing utility in cancer therapy, demonstrating significant promise as a therapeutic approach. Nanomaterials possess favorable tumor-targeting characteristics that can be effectively combined with ferroptosis drugs. This synergy aims to minimize drug toxicity while augmenting therapeutic efficacy in the treatment of cancer (<xref ref-type="bibr" rid="B113">Xiong et al., 2019</xref>; <xref ref-type="bibr" rid="B19">Chen et al., 2023</xref>).</p>
<p>Natural phytochemicals found in herbs, cereals, seeds, and other plants offer a potential alternative, as they possess bioactive compounds with protective or disease-preventing properties (<xref ref-type="bibr" rid="B5">Bak et al., 2016</xref>). Compared to synthetic compounds, natural phytochemicals are known for their lower toxicity, fewer side effects, higher safety, and diverse chemical profiles (<xref ref-type="bibr" rid="B53">Kapinova et al., 2018</xref>). Exploring the vast array of natural phytochemicals holds great potential for discovering effective ferroptosis inducers.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Author contributions</title>
<p>CX and YC conceptualized the manuscript. CX, YC, QY, JS, and YJ collected the literature, wrote the manuscript, and made the figures. XG edited and made significant revisions to the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s6">
<title>Funding</title>
<p>This study was supported by National Natural Science Foundation of China (No. 82074438).</p>
</sec>
<ack>
<p>We thank collaborators for their contributions to the publications cited in this review article. The research field in ferroptosis is rapidly growing, and we apologize for not being able to cite all the recent publications, due to space limitation.</p>
</ack>
<sec sec-type="COI-statement" id="s7">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akhtar</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Saleem</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rasul</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Faran Ashraf Baig</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Bin-Jumah</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abdel Daim</surname>
<given-names>M. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Anticancer natural medicines: an overview of cell signaling and other targets of anticancer phytochemicals</article-title>. <source>Eur. J. Pharmacol.</source> <volume>888</volume>, <fpage>173488</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173488</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al Zahrani</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>El-Shishtawy</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Asiri</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Recent developments of gallic acid derivatives and their hybrids in medicinal chemistry: a review</article-title>. <source>Eur. J. Med. Chem.</source> <volume>204</volume>, <fpage>112609</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112609</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Quercetin promotes TFEB nuclear translocation and activates lysosomal degradation of ferritin to induce ferroptosis in breast cancer cells</article-title>. <source>Comput. Intell. Neurosci.</source> <volume>2022</volume>, <fpage>5299218</fpage>. <pub-id pub-id-type="doi">10.1155/2022/5299218</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrieu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Belkina</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Denis</surname>
<given-names>G. V.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Clinical trials for BET inhibitors run ahead of the science</article-title>. <source>Drug Discov. Today Technol.</source> <volume>19</volume>, <fpage>45</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2016.06.004</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bak</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Das Gupta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wahler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Role of dietary bioactive natural products in estrogen receptor-positive breast cancer</article-title>. <source>Semin. Cancer Biol.</source> <volume>40-41</volume>, <fpage>170</fpage>&#x2013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2016.03.001</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldwin</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Osheroff</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Etoposide, topoisomerase II and cancer</article-title>. <source>Curr. Med. Chem. Anticancer Agents</source> <volume>5</volume> (<issue>4</issue>), <fpage>363</fpage>&#x2013;<lpage>372</lpage>. <pub-id pub-id-type="doi">10.2174/1568011054222364</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bazhabayi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>CircGFRA1 facilitates the malignant progression of HER-2-positive breast cancer via acting as a sponge of miR-1228 and enhancing AIFM2 expression</article-title>. <source>J. Cell. Mol. Med.</source> <volume>25</volume> (<issue>21</issue>), <fpage>10248</fpage>&#x2013;<lpage>10256</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.16963</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beatty</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tyurina</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Tyurin</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Samovich</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nicolas</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Ferroptotic cell death triggered by conjugated linolenic acids is mediated by ACSL1</article-title>. <source>Nat. Commun.</source> <volume>12</volume> (<issue>1</issue>), <fpage>2244</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-22471-y</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bersuker</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hendricks</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Magtanong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>P. H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis</article-title>. <source>Nature</source> <volume>575</volume> (<issue>7784</issue>), <fpage>688</fpage>&#x2013;<lpage>692</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1705-2</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>M.-L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>P.-W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.-W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>C. L.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Formosanin C suppresses cancer cell proliferation and migration by impeding autophagy machinery</article-title>. <source>Kaohsiung J. Med. Sci.</source> <volume>39</volume> (<issue>5</issue>), <fpage>489</fpage>&#x2013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1002/kjm2.12658</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Curcumin suppresses tumorigenesis by ferroptosis in breast cancer</article-title>. <source>PloS one</source> <volume>17</volume> (<issue>1</issue>), <fpage>e0261370</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0261370</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caracas</surname>
<given-names>HCPM</given-names>
</name>
<name>
<surname>Maciel</surname>
<given-names>J. V. B.</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>PMRES</given-names>
</name>
<name>
<surname>de Souza</surname>
<given-names>M. M. G.</given-names>
</name>
<name>
<surname>Maia</surname>
<given-names>L. C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The use of lidocaine as an anti-inflammatory substance: a systematic review</article-title>. <source>J. Dent.</source> <volume>37</volume> (<issue>2</issue>), <fpage>93</fpage>&#x2013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdent.2008.10.005</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>G.-Q.</given-names>
</name>
<name>
<surname>Benthani</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bian</surname>
<given-names>Z. X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020b</year>). <article-title>Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis</article-title>. <source>Cell. death Differ.</source> <volume>27</volume> (<issue>1</issue>), <fpage>242</fpage>&#x2013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-019-0352-3</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Vulnerability of triple-negative breast cancer to saponin Formosanin C-induced ferroptosis</article-title>. <source>Antioxidants (Basel, Switz.</source> <volume>11</volume> (<issue>2</issue>), <fpage>298</fpage>. <pub-id pub-id-type="doi">10.3390/antiox11020298</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022c</year>). <article-title>Metformin may induce ferroptosis by inhibiting autophagy via lncRNA H19 in breast cancer</article-title>. <source>FEBS open bio</source> <volume>12</volume> (<issue>1</issue>), <fpage>146</fpage>&#x2013;<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1002/2211-5463.13314</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2022a</year>). <article-title>Formosanin C induces autophagy-mediated apoptosis in multiple myeloma cells through the PI3K/AKT/mTOR signaling pathway</article-title>. <source>Hematology</source> <volume>27</volume> (<issue>1</issue>), <fpage>977</fpage>&#x2013;<lpage>986</lpage>. <pub-id pub-id-type="doi">10.1080/16078454.2022.2117126</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Broadening horizons: the role of ferroptosis in cancer</article-title>. <source>Nat. Rev. Clin. Oncol.</source> <volume>18</volume> (<issue>5</issue>), <fpage>280</fpage>&#x2013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1038/s41571-020-00462-0</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020a</year>). <article-title>Iron metabolism in ferroptosis</article-title>. <source>Front. Cell. Dev. Biol.</source> <volume>8</volume>, <fpage>590226</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2020.590226</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ping</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy</article-title>. <source>Acta biomater.</source> <volume>159</volume>, <fpage>275</fpage>&#x2013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2023.01.050</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christensen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kristensen</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Bartels</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Bliddal</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Astrup</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials</article-title>. <source>Lancet</source> <volume>370</volume> (<issue>9600</issue>), <fpage>1706</fpage>&#x2013;<lpage>1713</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61721-8</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cory</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Passarelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Szeto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tamez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mattei</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The role of polyphenols in human health and food systems: a mini-review</article-title>. <source>Front. Nutr.</source> <volume>5</volume>, <fpage>87</fpage>. <pub-id pub-id-type="doi">10.3389/fnut.2018.00087</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Tung tree (vernicia fordii, hemsl.) genome and transcriptome sequencing reveals Co-ordinate up-regulation of fatty acid &#x3b2;-oxidation and triacylglycerol biosynthesis pathways during eleostearic acid accumulation in seeds</article-title>. <source>Plant Cell. Physiol.</source> <volume>59</volume> (<issue>10</issue>), <fpage>1990</fpage>&#x2013;<lpage>2003</lpage>. <pub-id pub-id-type="doi">10.1093/pcp/pcy117</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Dihydroartemisinin: a potential natural anticancer drug</article-title>. <source>Int. J. Biol. Sci.</source> <volume>17</volume> (<issue>2</issue>), <fpage>603</fpage>&#x2013;<lpage>622</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.50364</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells</article-title>. <source>J. Hematol. Oncol.</source> <volume>14</volume> (<issue>1</issue>), <fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-020-01016-8</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Lemberg</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Lamprecht</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zaitsev</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Gleason</surname>
<given-names>C. E.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Ferroptosis: an iron-dependent form of nonapoptotic cell death</article-title>. <source>Cell.</source> <volume>149</volume> (<issue>5</issue>), <fpage>1060</fpage>&#x2013;<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dodo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Minato</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Noguchi-Yachide</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Suganuma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Antiproliferative and apoptosis-inducing activities of alkyl gallate and gallamide derivatives related to (-)-epigallocatechin gallate</article-title>. <source>Bioorg Med. Chem.</source> <volume>16</volume> (<issue>17</issue>), <fpage>7975</fpage>&#x2013;<lpage>7982</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2008.07.063</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doll</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Conrad</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Iron and ferroptosis: a still ill-defined liaison</article-title>. <source>IUBMB Life</source> <volume>69</volume> (<issue>6</issue>), <fpage>423</fpage>&#x2013;<lpage>434</lpage>. <pub-id pub-id-type="doi">10.1002/iub.1616</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doll</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Freitas</surname>
<given-names>F. P.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Aldrovandi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Ingold</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>FSP1 is a glutathione-independent ferroptosis suppressor</article-title>. <source>Nature</source> <volume>575</volume> (<issue>7784</issue>), <fpage>693</fpage>&#x2013;<lpage>698</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1707-0</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doll</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Proneth</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tyurina</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Panzilius</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ingold</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition</article-title>. <source>Nat. Chem. Biol.</source> <volume>13</volume> (<issue>1</issue>), <fpage>91</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.2239</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lessnick</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>W. C.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells</article-title>. <source>Cancer Cell.</source> <volume>3</volume> (<issue>3</issue>), <fpage>285</fpage>&#x2013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1016/s1535-6108(03)00050-3</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dowdle</surname>
<given-names>W. E.</given-names>
</name>
<name>
<surname>Nyfeler</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nagel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Elling</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Triantafellow</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis <italic>in vivo</italic>
</article-title>. <source>Nat. Cell. Biol.</source> <volume>16</volume> (<issue>11</issue>), <fpage>1069</fpage>&#x2013;<lpage>1079</lpage>. <pub-id pub-id-type="doi">10.1038/ncb3053</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>A novel anticancer property of Lycium barbarum polysaccharide in triggering ferroptosis of breast cancer cells</article-title>. <source>J. Zhejiang Univ. Sci. B</source> <volume>23</volume> (<issue>4</issue>), <fpage>286</fpage>&#x2013;<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1631/jzus.B2100748</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Ketamine inhibits colorectal cancer cells malignant potential via blockage of NMDA receptor</article-title>. <source>Exp. Mol. Pathol.</source> <volume>107</volume>, <fpage>171</fpage>&#x2013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexmp.2019.02.004</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dundee</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Knox</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>G. W.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pandit</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Bovill</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>1970</year>). <article-title>Ketamine as an induction agent in anaesthetics</article-title>. <source>Lancet</source> <volume>1</volume> (<issue>7661</issue>), <fpage>1370</fpage>&#x2013;<lpage>1371</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(70)91273-0</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elakkad</surname>
<given-names>Y. E.</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>S. N. S.</given-names>
</name>
<name>
<surname>Abuelezz</surname>
<given-names>N. Z.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Potentiating the cytotoxic activity of a novel simvastatin-loaded cubosome against breast cancer cells: insights on dual cell death via ferroptosis and apoptosis</article-title>. <source>Breast cancer</source> <volume>13</volume>, <fpage>675</fpage>&#x2013;<lpage>689</lpage>. <pub-id pub-id-type="doi">10.2147/bctt.S336712</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Klionsky</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The machinery of macroautophagy</article-title>. <source>Cell. Res.</source> <volume>24</volume> (<issue>1</issue>), <fpage>24</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2013.168</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gou</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Synthesis and anticancer activity of some novel 2-phenazinamine derivatives</article-title>. <source>Eur. J. Med. Chem.</source> <volume>69</volume>, <fpage>1</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2013.07.017</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geyer</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Forster</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lindquist</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Romieu</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Pienkowski</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Lapatinib plus capecitabine for HER2-positive advanced breast cancer</article-title>. <source>N. Engl. J. Med.</source> <volume>355</volume> (<issue>26</issue>), <fpage>2733</fpage>&#x2013;<lpage>2743</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa064320</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomme</surname>
<given-names>P. T.</given-names>
</name>
<name>
<surname>McCann</surname>
<given-names>K. B.</given-names>
</name>
<name>
<surname>Bertolini</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Transferrin: structure, function and potential therapeutic actions</article-title>. <source>Drug Discov. Today</source> <volume>10</volume> (<issue>4</issue>), <fpage>267</fpage>&#x2013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1016/S1359-6446(04)03333-1</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gradishar</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aft</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Agnese</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Allison</surname>
<given-names>K. H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology</article-title>. <source>J. Natl. Compr. Canc Netw.</source> <volume>20</volume> (<issue>6</issue>), <fpage>691</fpage>&#x2013;<lpage>722</lpage>. <pub-id pub-id-type="doi">10.6004/jnccn.2022.0030</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haque</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brazeau</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>A. R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds</article-title>. <source>Eur. J. Cancer</source> <volume>149</volume>, <fpage>165</fpage>&#x2013;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2021.03.009</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hargreaves</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Heaton</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Mantle</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Disorders of human coenzyme Q10 metabolism: an overview</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume> (<issue>18</issue>), <fpage>6695</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21186695</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>G.-N.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>N.-R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F. S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Ketamine induces ferroptosis of liver cancer cells by targeting lncRNA PVT1/miR-214-3p/GPX4</article-title>. <source>Drug Des. Dev. Ther.</source> <volume>15</volume>, <fpage>3965</fpage>&#x2013;<lpage>3978</lpage>. <pub-id pub-id-type="doi">10.2147/DDDT.S332847</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<collab>Heading C. Siramesine H Lundbeck</collab> (<year>2001</year>). <article-title>Siramesine H Lundbeck</article-title>. <source>Curr. Opin. Investig. Drugs</source> <volume>2</volume> (<issue>2</issue>), <fpage>266</fpage>&#x2013;<lpage>270</lpage>.</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heckman-Stoddard</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>DeCensi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sahasrabuddhe</surname>
<given-names>V. V.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>L. G.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Repurposing metformin for the prevention of cancer and cancer recurrence</article-title>. <source>Diabetologia</source> <volume>60</volume> (<issue>9</issue>), <fpage>1639</fpage>&#x2013;<lpage>1647</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-017-4372-6</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hishikawa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shindou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Taguchi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>105</volume> (<issue>8</issue>), <fpage>2830</fpage>&#x2013;<lpage>2835</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0712245105</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lotze</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Zeh</surname>
<given-names>H. J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Autophagy promotes ferroptosis by degradation of ferritin</article-title>. <source>Autophagy</source> <volume>12</volume> (<issue>8</issue>), <fpage>1425</fpage>&#x2013;<lpage>1428</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2016.1187366</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Metformin induces ferroptosis by targeting miR-324-3p/GPX4 axis in breast cancer</article-title>. <source>Acta biochimica biophysica Sinica</source> <volume>53</volume> (<issue>3</issue>), <fpage>333</fpage>&#x2013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1093/abbs/gmaa180</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>SIRT3-mediated autophagy contributes to ferroptosis-induced anticancer by inducing the formation of BECN1-SLC7A11 complex</article-title>. <source>Biochem. Pharmacol.</source> <volume>213</volume>, <fpage>115592</fpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2023.115592</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Barbacioru</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sad&#xe9;e</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance</article-title>. <source>Cancer Res.</source> <volume>65</volume> (<issue>16</issue>), <fpage>7446</fpage>&#x2013;<lpage>7454</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4267</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussain</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hakkim</surname>
<given-names>F. L.</given-names>
</name>
<name>
<surname>Westermann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Glycyrrhetinic acid: a promising scaffold for the discovery of anticancer agents</article-title>. <source>Expert Opin. Drug Discov.</source> <volume>16</volume> (<issue>12</issue>), <fpage>1497</fpage>&#x2013;<lpage>1516</lpage>. <pub-id pub-id-type="doi">10.1080/17460441.2021.1956901</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jing</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Levistilide a induces ferroptosis by activating the Nrf2/HO-1 signaling pathway in breast cancer cells</article-title>. <source>Drug Des. Dev. Ther.</source> <volume>16</volume>, <fpage>2981</fpage>&#x2013;<lpage>2993</lpage>. <pub-id pub-id-type="doi">10.2147/dddt.S374328</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapinova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kubatka</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Golubnitschaja</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Kello</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zubor</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Solar</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Dietary phytochemicals in breast cancer research: anticancer effects and potential utility for effective chemoprevention</article-title>. <source>Environ. Health Prev. Med.</source> <volume>23</volume> (<issue>1</issue>), <fpage>36</fpage>. <pub-id pub-id-type="doi">10.1186/s12199-018-0724-1</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kasukabe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kumakura</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Menin-MLL inhibitors induce ferroptosis and enhance the anti-proliferative activity of auranofin in several types of cancer cells</article-title>. <source>Int. J. Oncol.</source> <volume>57</volume> (<issue>4</issue>), <fpage>1057</fpage>&#x2013;<lpage>1071</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2020.5116</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khorsandi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kianmehr</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hosseinmardi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hosseinzadeh</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Anti-cancer effect of gallic acid in presence of low level laser irradiation: ROS production and induction of apoptosis and ferroptosis</article-title>. <source>Cancer Cell. Int.</source> <volume>20</volume>, <fpage>18</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-020-1100-y</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kourie</surname>
<given-names>H. R.</given-names>
</name>
<name>
<surname>El Rassy</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Clatot</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>de Azambuja</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lambertini</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib</article-title>. <source>Onco Targets Ther.</source> <volume>10</volume>, <fpage>3363</fpage>&#x2013;<lpage>3372</lpage>. <pub-id pub-id-type="doi">10.2147/OTT.S122397</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnaiah</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Almeida</surname>
<given-names>N. R.</given-names>
</name>
<name>
<surname>Udumula</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chhonker</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Abdelmoaty</surname>
<given-names>M. M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Synthesis, biological evaluation, and metabolic stability of phenazine derivatives as antibacterial agents</article-title>. <source>Eur. J. Med. Chem.</source> <volume>143</volume>, <fpage>936</fpage>&#x2013;<lpage>947</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2017.11.026</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>K&#xfc;ch</surname>
<given-names>E.-M.</given-names>
</name>
<name>
<surname>Vellaramkalayil</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lehnen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Br&#xfc;gger</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sreemmel</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Differentially localized acyl-CoA synthetase 4 isoenzymes mediate the metabolic channeling of fatty acids towards phosphatidylinositol</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1841</volume> (<issue>2</issue>), <fpage>227</fpage>&#x2013;<lpage>239</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2013.10.018</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>K&#xfc;hn</surname>
<given-names>L. C.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Iron regulatory proteins and their role in controlling iron metabolism</article-title>. <source>Metallomics</source> <volume>7</volume> (<issue>2</issue>), <fpage>232</fpage>&#x2013;<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1039/c4mt00164h</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>W. K.</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>K.-H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>E. W.</given-names>
</name>
</person-group> (<year>2021b</year>). <article-title>Lipid metabolism and ferroptosis</article-title>. <source>Biology</source> <volume>10</volume> (<issue>3</issue>), <fpage>184</fpage>. <pub-id pub-id-type="doi">10.3390/biology10030184</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Carlisle</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Peppers</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Doshi</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Spears</surname>
<given-names>M. E.</given-names>
</name>
<etal/>
</person-group> (<year>2021c</year>). <article-title>xCT-driven expression of GPX4 determines sensitivity of breast cancer cells to ferroptosis inducers</article-title>. <source>Antioxidants (Basel, Switz.</source> <volume>10</volume> (<issue>2</issue>), <fpage>317</fpage>. <pub-id pub-id-type="doi">10.3390/antiox10020317</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Carlisle</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Peppers</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Doshi</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Spears</surname>
<given-names>M. E.</given-names>
</name>
<etal/>
</person-group> (<year>2021a</year>). <article-title>xCT-driven expression of GPX4 determines sensitivity of breast cancer cells to ferroptosis inducers</article-title>. <source>Antioxidants (Basel, Switz.</source> <volume>10</volume> (<issue>2</issue>), <fpage>317</fpage>. <pub-id pub-id-type="doi">10.3390/antiox10020317</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Ketamine suppresses proliferation and induces ferroptosis and apoptosis of breast cancer cells by targeting KAT5/GPX4 axis</article-title>. <source>Biochem. biophysical Res. Commun.</source> <volume>585</volume>, <fpage>111</fpage>&#x2013;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2021.11.029</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism</article-title>. <source>Cell. death Dis.</source> <volume>13</volume> (<issue>9</issue>), <fpage>808</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-022-05242-5</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Transcriptome investigation and <italic>in vitro</italic> verification of curcumin-induced HO-1 as a feature of ferroptosis in breast cancer cells</article-title>. <source>Oxidative Med. Cell. Longev.</source> <volume>2020</volume>, <fpage>3469840</fpage>. <pub-id pub-id-type="doi">10.1155/2020/3469840</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Masters</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Both Bupivacaine and Levobupivacaine inhibit colon cancer cell growth but not melanoma cells <italic>in vitro</italic>
</article-title>. <source>J. Anesth.</source> <volume>33</volume> (<issue>1</issue>), <fpage>17</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1007/s00540-018-2577-6</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Danshen improves survival of patients with breast cancer and Dihydroisotanshinone I induces ferroptosis and apoptosis of breast cancer cells</article-title>. <source>Front. Pharmacol.</source> <volume>10</volume>, <fpage>1226</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.01226</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kuang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Klionsky</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Autophagy-dependent ferroptosis: machinery and regulation</article-title>. <source>Cell. Chem. Biol.</source> <volume>27</volume> (<issue>4</issue>), <fpage>420</fpage>&#x2013;<lpage>435</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2020.02.005</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S.-J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F. H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Design, synthesis, and biological evaluation of nitroisoxazole-containing spiro[pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit breast adenocarcinoma cell proliferation</article-title>. <source>Eur. J. Med. Chem.</source> <volume>217</volume>, <fpage>113359</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113359</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Henson</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>S. B.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells</article-title>. <source>Cell. death Dis.</source> <volume>7</volume> (<issue>7</issue>), <fpage>e2307</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2016.208</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mai</surname>
<given-names>T. T.</given-names>
</name>
<name>
<surname>Hama&#xef;</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hienzsch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ca&#xf1;eque</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wicinski</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Salinomycin kills cancer stem cells by sequestering iron in lysosomes</article-title>. <source>Nat. Chem.</source> <volume>9</volume> (<issue>10</issue>), <fpage>1025</fpage>&#x2013;<lpage>1033</lpage>. <pub-id pub-id-type="doi">10.1038/nchem.2778</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Man</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Formosanin C-inhibited pulmonary metastasis through repression of matrix metalloproteinases on mouse lung adenocarcinoma</article-title>. <source>Cancer Biol. Ther.</source> <volume>11</volume> (<issue>6</issue>), <fpage>592</fpage>&#x2013;<lpage>598</lpage>. <pub-id pub-id-type="doi">10.4161/cbt.11.6.14668</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mancias</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gygi</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Kimmelman</surname>
<given-names>A. C.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy</article-title>. <source>Nature</source> <volume>509</volume> (<issue>7498</issue>), <fpage>105</fpage>&#x2013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1038/nature13148</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53</article-title>. <source>Cancer Res.</source> <volume>78</volume> (<issue>13</issue>), <fpage>3484</fpage>&#x2013;<lpage>3496</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3454</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meresse</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dechaux</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Monneret</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bertounesque</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Etoposide: discovery and medicinal chemistry</article-title>. <source>Curr. Med. Chem.</source> <volume>11</volume> (<issue>18</issue>), <fpage>2443</fpage>&#x2013;<lpage>2466</lpage>. <pub-id pub-id-type="doi">10.2174/0929867043364531</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muckenthaler</surname>
<given-names>M. U.</given-names>
</name>
<name>
<surname>Galy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hentze</surname>
<given-names>M. W.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network</article-title>. <source>Annu. Rev. Nutr.</source> <volume>28</volume>, <fpage>197</fpage>&#x2013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.nutr.28.061807.155521</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagpal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Redvers</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ayton</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fuentes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tavancheh</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(&#x2b;ve) breast cancer metastasis</article-title>. <source>Breast cancer Res. BCR</source> <volume>21</volume> (<issue>1</issue>), <fpage>94</fpage>. <pub-id pub-id-type="doi">10.1186/s13058-019-1177-1</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ning</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Atorvastatin treatment ameliorates cardiac function and remodeling induced by isoproterenol attack through mitigation of ferroptosis</article-title>. <source>Biochem. biophysical Res. Commun.</source> <volume>574</volume>, <fpage>39</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2021.08.017</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Quan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy</article-title>. <source>Biomaterials</source> <volume>277</volume>, <fpage>121110</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121110</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozkan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bakar-Ates</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2023a</year>). <article-title>Etoposide in combination with erastin synergistically altered iron homeostasis and induced ferroptotic cell death through regulating IREB2/FPN1 expression in estrogen receptor positive-breast cancer cells</article-title>. <source>Life Sci.</source> <volume>312</volume>, <fpage>121222</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2022.121222</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozkan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bakar-Ates</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2023b</year>). <article-title>Etoposide in combination with erastin synergistically altered iron homeostasis and induced ferroptotic cell death through regulating IREB2/FPN1 expression in estrogen receptor positive-breast cancer cells</article-title>. <source>Life Sci.</source> <volume>312</volume>, <fpage>121222</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2022.121222</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pernicova</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Korbonits</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Metformin--mode of action and clinical implications for diabetes and cancer</article-title>. <source>Nat. Rev. Endocrinol.</source> <volume>10</volume> (<issue>3</issue>), <fpage>143</fpage>&#x2013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1038/nrendo.2013.256</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabindran</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Discafani</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Rosfjord</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Floyd</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Golas</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase</article-title>. <source>Cancer Res.</source> <volume>64</volume> (<issue>11</issue>), <fpage>3958</fpage>&#x2013;<lpage>3965</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-2868</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizzollo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>More</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vangheluwe</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Agostinis</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The lysosome as a master regulator of iron metabolism</article-title>. <source>Trends Biochem. Sci.</source> <volume>46</volume> (<issue>12</issue>), <fpage>960</fpage>&#x2013;<lpage>975</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2021.07.003</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>R&#xf6;hrig</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Schulze</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The multifaceted roles of fatty acid synthesis in cancer</article-title>. <source>Nat. Rev. Cancer</source> <volume>16</volume> (<issue>11</issue>), <fpage>732</fpage>&#x2013;<lpage>749</lpage>. <pub-id pub-id-type="doi">10.1038/nrc.2016.89</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roohbakhsh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Iranshahy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iranshahi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Glycyrrhetinic acid and its derivatives: anti-cancer and cancer chemopreventive properties, mechanisms of action and structure- cytotoxic activity relationship</article-title>. <source>Curr. Med. Chem.</source> <volume>23</volume> (<issue>5</issue>), <fpage>498</fpage>&#x2013;<lpage>517</lpage>. <pub-id pub-id-type="doi">10.2174/0929867323666160112122256</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tamba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bannai</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins</article-title>. <source>J. Biol. Chem.</source> <volume>274</volume> (<issue>17</issue>), <fpage>11455</fpage>&#x2013;<lpage>11458</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.17.11455</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vakoc</surname>
<given-names>C. R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The mechanisms behind the therapeutic activity of BET bromodomain inhibition</article-title>. <source>Mol. Cell.</source> <volume>54</volume> (<issue>5</issue>), <fpage>728</fpage>&#x2013;<lpage>736</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2014.05.016</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith-Apeldoorn</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Veraart</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Spijker</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kamphuis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schoevers</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability</article-title>. <source>Lancet Psychiatry</source> <volume>9</volume> (<issue>11</issue>), <fpage>907</fpage>&#x2013;<lpage>921</lpage>. <pub-id pub-id-type="doi">10.1016/S2215-0366(22)00317-0</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sopik</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nofech-Mozes</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Narod</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The relationship between local recurrence and death in early-stage breast cancer</article-title>. <source>Breast Cancer Res. Treat.</source> <volume>155</volume> (<issue>1</issue>), <fpage>175</fpage>&#x2013;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1007/s10549-015-3666-y</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs</article-title>. <source>Cancer Lett.</source> <volume>483</volume>, <fpage>127</fpage>&#x2013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2020.02.015</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sui</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Emerging role of ferroptosis in breast cancer: new dawn for overcoming tumor progression</article-title>. <source>Pharmacol. Ther.</source> <volume>232</volume>, <fpage>107992</fpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107992</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sui</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (&#x2b;)-JQ1 in cancer cells</article-title>. <source>Cell. death Dis.</source> <volume>10</volume> (<issue>5</issue>), <fpage>331</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-019-1564-7</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Propofol inhibits proliferation and augments the anti-tumor effect of doxorubicin and paclitaxel partly through promoting ferroptosis in triple-negative breast cancer cells</article-title>. <source>Front. Oncol.</source> <volume>12</volume>, <fpage>837974</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2022.837974</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X. Y.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>Lidocaine promoted ferroptosis by targeting miR-382-5p/SLC7A11 Axis in ovarian and breast cancer</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>681223</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.681223</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Linghu</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2021b</year>). <article-title>Ferroptosis: a promising target for cancer immunotherapy</article-title>. <source>Am. J. cancer Res.</source> <volume>11</volume> (<issue>12</issue>), <fpage>5856</fpage>&#x2013;<lpage>5863</lpage>.</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sung</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ferlay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Laversanne</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soerjomataram</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J. Clin.</source> <volume>71</volume> (<issue>3</issue>), <fpage>209</fpage>&#x2013;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020</year>). <source>Ferroptosis. <italic>Curr. Biol. CB</italic>
</source> <volume>30</volume> (<issue>21</issue>), <fpage>R1292-R1297</fpage>&#x2013;<lpage>R97</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2020.09.068</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>H. S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Antifungal activity of essential oil and plant-derived natural compounds against Aspergillus flavus</article-title>. <source>Antibiot. (Basel)</source> <volume>11</volume> (<issue>12</issue>), <fpage>1727</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics11121727</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tolaney</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>New HER2-positive targeting agents in clinical practice</article-title>. <source>Curr. Oncol. Rep.</source> <volume>16</volume> (<issue>1</issue>), <fpage>359</fpage>. <pub-id pub-id-type="doi">10.1007/s11912-013-0359-8</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Isoliquiritin modulates ferroptosis via NF-&#x3ba;B signaling inhibition and alleviates doxorubicin resistance in breast cancer</article-title>. <source>Immunopharmacol. Immunotoxicol.</source> <volume>2023</volume>, <fpage>443</fpage>&#x2013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1080/08923973.2023.2165943</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis</article-title>. <source>Biochem. biophysical Res. Commun.</source> <volume>558</volume>, <fpage>216</fpage>&#x2013;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.08.113</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Gij&#xf3;n</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J. K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>CD8&#x2b; T cells regulate tumour ferroptosis during cancer immunotherapy</article-title>. <source>Nature</source> <volume>569</volume> (<issue>7755</issue>), <fpage>270</fpage>&#x2013;<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1170-y</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Eupaformosanin induces apoptosis and ferroptosis through ubiquitination of mutant p53 in triple-negative breast cancer</article-title>. <source>Eur. J. Pharmacol.</source> <volume>924</volume>, <fpage>174970</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2022.174970</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>L.-Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.-N.</given-names>
</name>
</person-group> (<year>2021b</year>). &#x201c;<article-title>Arnicolide D inhibits oxidative stress-induced breast cancer cell growth and invasion through apoptosis</article-title>,&#x201d; in <source>Ferroptosis, and Parthanatos. Anti-cancer agents in medicinal chemistry 202210</source>. <comment>2174/1871520623666221208102021</comment>.</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2021a</year>). <article-title>Glycyrrhetinic acid induces oxidative/nitrative stress and drives ferroptosis through activating NADPH oxidases and iNOS, and depriving glutathione in triple-negative breast cancer cells</article-title>. <source>Free Radic. Biol. Med.</source> <volume>173</volume>, <fpage>41</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.07.019</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williamson</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The role of polyphenols in modern nutrition</article-title>. <source>Nutr. Bull.</source> <volume>42</volume> (<issue>3</issue>), <fpage>226</fpage>&#x2013;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1111/nbu.12278</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wood</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Truesdale</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>O. B.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hassell</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dickerson</surname>
<given-names>S. H.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</article-title>. <source>Cancer Res.</source> <volume>64</volume> (<issue>18</issue>), <fpage>6652</fpage>&#x2013;<lpage>6659</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1168</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Ferroptosis as a novel therapeutic target for cardiovascular disease</article-title>. <source>Theranostics</source> <volume>11</volume> (<issue>7</issue>), <fpage>3052</fpage>&#x2013;<lpage>3059</lpage>. <pub-id pub-id-type="doi">10.7150/thno.54113</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis</article-title>. <source>J. Hematol. Oncol.</source> <volume>15</volume> (<issue>1</issue>), <fpage>72</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-022-01297-1</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X. C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>F. H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Identification of a new natural biflavonoids against breast cancer cells induced ferroptosis via the mitochondrial pathway</article-title>. <source>Bioorg. Chem.</source> <volume>109</volume>, <fpage>104744</fpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2021.104744</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X. C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>P. S.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Cytotoxic effects of the biflavonoids isolated from Selaginella trichoclada on MCF-7 cells and its potential mechanism</article-title>. <source>Bioorg. Med. Chem. Lett.</source> <volume>56</volume>, <fpage>128486</fpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2021.128486</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Intracellular cascade activated nanosystem for improving ER&#x2b; breast cancer therapy through attacking GSH-mediated metabolic vulnerability</article-title>. <source>J. Control. release official J. Control. Release Soc.</source> <volume>309</volume>, <fpage>145</fpage>&#x2013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2019.07.029</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Non-coding RNA in cancer</article-title>. <source>Essays Biochem.</source> <volume>65</volume> (<issue>4</issue>), <fpage>625</fpage>&#x2013;<lpage>639</lpage>. <pub-id pub-id-type="doi">10.1042/EBC20200032</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Advances in phenazines over the past decade: review of their pharmacological activities, mechanisms of action, biosynthetic pathways and synthetic strategies</article-title>. <source>Mar. Drugs</source> <volume>19</volume> (<issue>11</issue>), <fpage>610</fpage>. <pub-id pub-id-type="doi">10.3390/md19110610</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2023a</year>). <article-title>Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy</article-title>. <source>Cell. metab.</source> <volume>35</volume> (<issue>1</issue>), <fpage>84</fpage>&#x2013;<lpage>100.e8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2022.09.021</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2023b</year>). <article-title>Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy</article-title>. <source>Cell. metab.</source> <volume>35</volume> (<issue>1</issue>), <fpage>84</fpage>&#x2013;<lpage>100.e8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2022.09.021</pub-id>
</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>Q. P.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer</article-title>. <source>Curr. Drug Targets</source> <volume>11</volume> (<issue>6</issue>), <fpage>733</fpage>&#x2013;<lpage>744</lpage>. <pub-id pub-id-type="doi">10.2174/138945010791170842</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>Metabolic intervention nanoparticles for triple-negative breast cancer therapy via overcoming FSP1-mediated ferroptosis resistance</article-title>. <source>Adv. Healthc. Mater.</source> <volume>11</volume> (<issue>13</issue>), <fpage>e2102799</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202102799</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer</article-title>. <source>J. Exp. Clin. cancer Res. CR</source> <volume>40</volume> (<issue>1</issue>), <fpage>206</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-021-02012-7</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>SriRamaratnam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Welsch</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Viswanathan</surname>
<given-names>V. S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Regulation of ferroptotic cancer cell death by GPX4</article-title>. <source>Cell.</source> <volume>156</volume> (<issue>1-2</issue>), <fpage>317</fpage>&#x2013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.12.010</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Phenazine derivatives attenuate the stemness of breast cancer cells through triggering ferroptosis</article-title>. <source>Cell. Mol. life Sci. CMLS</source> <volume>79</volume> (<issue>7</issue>), <fpage>360</fpage>. <pub-id pub-id-type="doi">10.1007/s00018-022-04384-1</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>M.-Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>Role of ferroptosis in neurological diseases</article-title>. <source>Neurosci. Lett.</source> <volume>747</volume>, <fpage>135614</fpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2020.135614</pub-id>
</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Men</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Simvastatin induced ferroptosis for triple-negative breast cancer therapy</article-title>. <source>J. nanobiotechnology</source> <volume>19</volume> (<issue>1</issue>), <fpage>311</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-021-01058-1</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yap</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lopez-Olivo</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Dubowitz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hiller</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Riedel</surname>
<given-names>B.</given-names>
</name>
</person-group>
<collab>Global Onco-Anesthesia Research Collaboration Group</collab> (<year>2019</year>). <article-title>Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia</article-title>. <source>Can. J. Anaesth.</source> <volume>66</volume> (<issue>5</issue>), <fpage>546</fpage>&#x2013;<lpage>561</lpage>. <pub-id pub-id-type="doi">10.1007/s12630-019-01330-x</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>METTL16 epigenetically enhances GPX4 expression via m6A modification to promote breast cancer progression by inhibiting ferroptosis</article-title>. <source>Biochem. biophysical Res. Commun.</source> <volume>638</volume>, <fpage>1</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2022.10.065</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhuo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Ferroptosis: final destination for cancer?</article-title> <source>Cell. Prolif.</source> <volume>53</volume> (<issue>3</issue>), <fpage>e12761</fpage>. <pub-id pub-id-type="doi">10.1111/cpr.12761</pub-id>
</citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Tetrandrine citrate suppresses breast cancer via depletion of glutathione peroxidase 4 and activation of nuclear receptor coactivator 4-mediated ferritinophagy</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>820593</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.820593</pub-id>
</citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Ferroptosis, a new form of cell death, and its relationships with tumourous diseases</article-title>. <source>J. Cell. Mol. Med.</source> <volume>21</volume> (<issue>4</issue>), <fpage>648</fpage>&#x2013;<lpage>657</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13008</pub-id>
</citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jian</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Sulfasalazine-induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor</article-title>. <source>Oncol. Rep.</source> <volume>42</volume> (<issue>2</issue>), <fpage>826</fpage>&#x2013;<lpage>838</lpage>. <pub-id pub-id-type="doi">10.3892/or.2019.7189</pub-id>
</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhai</surname>
<given-names>F. G.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Q. C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J. Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J. W.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Red ginseng polysaccharide exhibits anticancer activity through GPX4 downregulation-induced ferroptosis</article-title>. <source>Pharm. Biol.</source> <volume>60</volume> (<issue>1</issue>), <fpage>909</fpage>&#x2013;<lpage>914</lpage>. <pub-id pub-id-type="doi">10.1080/13880209.2022.2066139</pub-id>
</citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2022a</year>). <article-title>Ferroptosis in cancer therapy: a novel approach to reversing drug resistance</article-title>. <source>Mol. Cancer</source> <volume>21</volume> (<issue>1</issue>), <fpage>47</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-022-01530-y</pub-id>
</citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>LINC00460 facilitates cell proliferation and inhibits ferroptosis in breast cancer through the miR-320a/MAL2 Axis</article-title>. <source>Technol. cancer Res. Treat.</source> <volume>22</volume>, <fpage>15330338231164359</fpage>. <pub-id pub-id-type="doi">10.1177/15330338231164359</pub-id>
</citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>Circular RNA RHOT1 promotes progression and inhibits ferroptosis via mir-106a-5p/STAT3 axis in breast cancer</article-title>. <source>Aging</source> <volume>13</volume> (<issue>6</issue>), <fpage>8115</fpage>&#x2013;<lpage>8126</lpage>. <pub-id pub-id-type="doi">10.18632/aging.202608</pub-id>
</citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>R. F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>K. d.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>K. X.</given-names>
</name>
</person-group> (<year>2022b</year>). <article-title>Alloimperatorin activates apoptosis, ferroptosis, and oxeiptosis to inhibit the growth and invasion of breast cancer cells <italic>in vitro</italic>
</article-title>. <source>Biochem. Cell. Biol. &#x3d; Biochimie Biol. Cell.</source> <volume>100</volume> (<issue>3</issue>), <fpage>213</fpage>&#x2013;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1139/bcb-2021-0399</pub-id>
</citation>
</ref>
<ref id="B136">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2022c</year>). <article-title>Atorvastatin induces mitochondria-dependent ferroptosis via the modulation of nrf2-xCT/GPx4 Axis</article-title>. <source>Front. Cell. Dev. Biol.</source> <volume>10</volume>, <fpage>806081</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2022.806081</pub-id>
</citation>
</ref>
<ref id="B137">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Imam</surname>
<given-names>M. U.</given-names>
</name>
</person-group> (<year>2021b</year>). <article-title>The regulatory effects and the signaling pathways of natural bioactive compounds on ferroptosis</article-title>. <source>Foods</source> <volume>10</volume> (<issue>12</issue>), <fpage>2952</fpage>. <pub-id pub-id-type="doi">10.3390/foods10122952</pub-id>
</citation>
</ref>
<ref id="B138">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>X.-D.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>T.-F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W. W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y. X.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma</article-title>. <source>Int. J. Cancer</source> <volume>136</volume> (<issue>11</issue>), <fpage>2556</fpage>&#x2013;<lpage>2565</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.29305</pub-id>
</citation>
</ref>
<ref id="B139">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Erastin-induced ferroptosis causes physiological and pathological changes in healthy tissues of mice</article-title>. <source>Mol. Med. Rep.</source> <volume>24</volume> (<issue>4</issue>), <fpage>713</fpage>. <pub-id pub-id-type="doi">10.3892/mmr.2021.12352</pub-id>
</citation>
</ref>
<ref id="B140">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Phytochemicals targeting ferroptosis: therapeutic opportunities and prospects for treating breast cancer</article-title>. <source>Pharm. (Basel, Switz.</source> <volume>15</volume> (<issue>11</issue>), <fpage>1360</fpage>. <pub-id pub-id-type="doi">10.3390/ph15111360</pub-id>
</citation>
</ref>
<ref id="B141">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The role of erastin in ferroptosis and its prospects in cancer therapy</article-title>. <source>Onco Targets Ther.</source> <volume>13</volume>, <fpage>5429</fpage>&#x2013;<lpage>5441</lpage>. <pub-id pub-id-type="doi">10.2147/OTT.S254995</pub-id>
</citation>
</ref>
<ref id="B142">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Klionsky</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Ferroptosis is a type of autophagy-dependent cell death</article-title>. <source>Semin. Cancer Biol.</source> <volume>66</volume>, <fpage>89</fpage>&#x2013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2019.03.002</pub-id>
</citation>
</ref>
<ref id="B143">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2022b</year>). <article-title>Natural compounds: a new perspective on targeting polarization and infiltration of tumor-associated macrophages in lung cancer</article-title>. <source>Biomed. Pharmacother.</source> <volume>151</volume>, <fpage>113096</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2022.113096</pub-id>
</citation>
</ref>
<ref id="B144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Polyphyllin &#x2162;-Induced ferroptosis in MDA-MB-231 triple-negative breast cancer cells can Be protected against by KLF4-mediated upregulation of xCT</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>670224</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.670224</pub-id>
</citation>
</ref>
<ref id="B145">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2022a</year>). <article-title>The role of ferroptosis in the development of acute and chronic kidney diseases</article-title>. <source>J. Cell. physiology</source> <volume>237</volume> (<issue>12</issue>), <fpage>4412</fpage>&#x2013;<lpage>4427</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.30901</pub-id>
</citation>
</ref>
</ref-list>
<sec id="s9">
<title>Glossary</title>
<table-wrap id="udT1" position="float">
<table>
<tbody valign="top">
<tr>
<td align="left">
<bold>ACSL</bold>
</td>
<td align="left">Acyl-CoA synthetase long-chain family member</td>
</tr>
<tr>
<td align="left">
<bold>ALOX</bold>
</td>
<td align="left">arachidonic acid lipoxygenase</td>
</tr>
<tr>
<td align="left">
<bold>ARNTL</bold>
</td>
<td align="left">aryl hydrocarbon receptor nuclear translocator-like protein</td>
</tr>
<tr>
<td align="left">
<bold>ATG</bold>
</td>
<td align="left">autophagy-related</td>
</tr>
<tr>
<td align="left">
<bold>&#x3e;AIFM2</bold>
</td>
<td align="left">apoptosis-inducing factor mitochondrial 2</td>
</tr>
<tr>
<td align="left">
<bold>AM5</bold>
</td>
<td align="left">ironomycin</td>
</tr>
<tr>
<td align="left">
<bold>AMPK</bold>
</td>
<td align="left">AMP-activated protein kinase</td>
</tr>
<tr>
<td align="left">
<bold>BC</bold>
</td>
<td align="left">Breast cancer</td>
</tr>
<tr>
<td align="left">
<bold>BET</bold>
</td>
<td align="left">bromodomain and extra-terminal domain</td>
</tr>
<tr>
<td align="left">
<bold>BETi</bold>
</td>
<td align="left">BET: bromodomain and extra-terminal domain inhibitors</td>
</tr>
<tr>
<td align="left">
<bold>BECN1</bold>
</td>
<td align="left">Beclin 1</td>
</tr>
<tr>
<td align="left">
<bold>BRD</bold>
</td>
<td align="left">bromodomain</td>
</tr>
<tr>
<td align="left">
<bold>CoQ10</bold>
</td>
<td align="left">Coenzyme Q10</td>
</tr>
<tr>
<td align="left">
<bold>C5H8</bold>
</td>
<td align="left">composed of multiple isoprene units</td>
</tr>
<tr>
<td align="left">
<bold>DAT</bold>
</td>
<td align="left">Dihydroartemisinin</td>
</tr>
<tr>
<td align="left">
<bold>ERBB</bold>
</td>
<td align="left">erythroblastic oncogene B</td>
</tr>
<tr>
<td align="left">
<bold>ER</bold>
</td>
<td align="left">estrogen receptor</td>
</tr>
<tr>
<td align="left">
<bold>FTH1</bold>
</td>
<td align="left">ferritin heavy chain 1</td>
</tr>
<tr>
<td align="left">
<bold>FTL</bold>
</td>
<td align="left">ferritin light chain</td>
</tr>
<tr>
<td align="left">
<bold>FPN</bold>
</td>
<td align="left">Ferroportin</td>
</tr>
<tr>
<td align="left">
<bold>FA</bold>
</td>
<td align="left">fatty acid</td>
</tr>
<tr>
<td align="left">
<bold>FSP1</bold>
</td>
<td align="left">ferroptosis inhibitor protein 1</td>
</tr>
<tr>
<td align="left">
<bold>FC</bold>
</td>
<td align="left">Formosanin C</td>
</tr>
<tr>
<td align="left">
<bold>Fe3O4@PCBMA</bold>
</td>
<td align="left">polymer-coated magnetic nanoparticles</td>
</tr>
<tr>
<td align="left">
<bold>GPX4</bold>
</td>
<td align="left">glutathione peroxidase 4</td>
</tr>
<tr>
<td align="left">
<bold>GSH</bold>
</td>
<td align="left">glutathione</td>
</tr>
<tr>
<td align="left">
<bold>GA</bold>
</td>
<td align="left">Gallic acid</td>
</tr>
<tr>
<td align="left">
<bold>HO-1</bold>
</td>
<td align="left">heme oxygenase-1</td>
</tr>
<tr>
<td align="left">
<bold>HMGCR</bold>
</td>
<td align="left">3-hydroxy-3-methylglutaryl coenzyme a reductase</td>
</tr>
<tr>
<td align="left">
<bold>HER</bold>
</td>
<td align="left">human epidermal growth factor receptor</td>
</tr>
<tr>
<td align="left">
<bold>H3K27ac</bold>
</td>
<td align="left">H3 lysine 27 acetylation</td>
</tr>
<tr>
<td align="left">
<bold>KAT5</bold>
</td>
<td align="left">kacetyltransferase 5</td>
</tr>
<tr>
<td align="left">
<bold>IRP</bold>
</td>
<td align="left">members of the iron regulatory protein</td>
</tr>
<tr>
<td align="left">
<bold>ISO</bold>
</td>
<td align="left">Isoliquiritin</td>
</tr>
<tr>
<td align="left">
<bold>lncRNA</bold>
</td>
<td align="left">long non-coding RNA</td>
</tr>
<tr>
<td align="left">
<bold>IREB</bold>
</td>
<td align="left">iron response element-binding protein</td>
</tr>
<tr>
<td align="left">
<bold>IRE</bold>
</td>
<td align="left">iron-responsive element</td>
</tr>
<tr>
<td align="left">
<bold>lncRNA</bold>
</td>
<td align="left">long non-coding RNA</td>
</tr>
<tr>
<td align="left">
<bold>LIP</bold>
</td>
<td align="left">labile iron pool</td>
</tr>
<tr>
<td align="left">
<bold>LPCAT3</bold>
</td>
<td align="left">lysophosphatidylcholine acyltransferase 3</td>
</tr>
<tr>
<td align="left">
<bold>LA</bold>
</td>
<td align="left">Levistilide A</td>
</tr>
<tr>
<td align="left">
<bold>LAR</bold>
</td>
<td align="left">Luminal androgen receptor</td>
</tr>
<tr>
<td align="left">
<bold>LBP</bold>
</td>
<td align="left">Lycium barbarum polysaccharide</td>
</tr>
<tr>
<td align="left">
<bold>m6A</bold>
</td>
<td align="left">N6-methyladenosine</td>
</tr>
<tr>
<td align="left">
<bold>mTOR</bold>
</td>
<td align="left">mammalian target of rapamycin</td>
</tr>
<tr>
<td align="left">
<bold>miRNA</bold>
</td>
<td align="left">microRNA</td>
</tr>
<tr>
<td align="left">
<bold>MDA</bold>
</td>
<td align="left">malondialdehyde</td>
</tr>
<tr>
<td align="left">
<bold>MVA</bold>
</td>
<td align="left">mevalonate</td>
</tr>
<tr>
<td align="left">
<bold>MDM2</bold>
</td>
<td align="left">mouse double minute 2</td>
</tr>
<tr>
<td align="left">
<bold>NCOA4</bold>
</td>
<td align="left">Nuclear receptor coactivator 4</td>
</tr>
<tr>
<td align="left">
<bold>NEDD4</bold>
</td>
<td align="left">neural precursor cell expressed developmentally downregulated 4</td>
</tr>
<tr>
<td align="left">
<bold>NEDD4L</bold>
</td>
<td align="left">neural precursor cell expressed developmentally downregulated 4-like</td>
</tr>
<tr>
<td align="left">
<bold>PLOOHs</bold>
</td>
<td align="left">phospholipid hydroperoxides</td>
</tr>
<tr>
<td align="left">
<bold>PLOHs</bold>
</td>
<td align="left">phospholipid alcohols</td>
</tr>
<tr>
<td align="left">
<bold>PUFAs</bold>
</td>
<td align="left">polyunsaturated fatty acids</td>
</tr>
<tr>
<td align="left">
<bold>RGP</bold>
</td>
<td align="left">Red ginseng polysaccharide</td>
</tr>
<tr>
<td align="left">
<bold>RNA pol II</bold>
</td>
<td align="left">RNA polymerase II</td>
</tr>
<tr>
<td align="left">
<bold>ROS</bold>
</td>
<td align="left">reactive oxygen species</td>
</tr>
<tr>
<td align="left">
<bold>REDOX</bold>
</td>
<td align="left">reduction-oxidation</td>
</tr>
<tr>
<td align="left">
<bold>RSL3</bold>
</td>
<td align="left">ras selective lethal 3</td>
</tr>
<tr>
<td align="left">
<bold>RF-A</bold>
</td>
<td align="left">Robustaflavone 7.5&#x2033;-dimethyl ether</td>
</tr>
<tr>
<td align="left">
<bold>siRNA</bold>
</td>
<td align="left">small interfering RNA</td>
</tr>
<tr>
<td align="left">
<bold>snRNA</bold>
</td>
<td align="left">small nuclear RNA</td>
</tr>
<tr>
<td align="left">
<bold>SIM</bold>
</td>
<td align="left">simvastatin</td>
</tr>
<tr>
<td align="left">
<bold>SLC1A5</bold>
</td>
<td align="left">solute carrier family 1 member 5</td>
</tr>
<tr>
<td align="left">
<bold>SLC7A11</bold>
</td>
<td align="left">solute carrier family 7 member 11</td>
</tr>
<tr>
<td align="left">
<bold>SLC3A2</bold>
</td>
<td align="left">solute carrier family 3 member 2</td>
</tr>
<tr>
<td align="left">
<bold>SAS</bold>
</td>
<td align="left">sulfasalazine</td>
</tr>
<tr>
<td align="left">
<bold>TNBC</bold>
</td>
<td align="left">triple-negative breast cancer</td>
</tr>
<tr>
<td align="left">
<bold>TFR/TFRC</bold>
</td>
<td align="left">transferrin receptor</td>
</tr>
<tr>
<td align="left">
<bold>TetC</bold>
</td>
<td align="left">Tetrandrine citrate</td>
</tr>
<tr>
<td align="left">
<bold>VDAC</bold>
</td>
<td align="left">voltage-dependent anion channels</td>
</tr>
<tr>
<td align="left">
<bold>&#x3b1;-ESA</bold>
</td>
<td align="left">Alpha eleostearic acid</td>
</tr>
<tr>
<td align="left">
<bold>ZnPP</bold>
</td>
<td align="left">Zinc Protoporphyrin</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</back>
</article>